A One-Pot Approach to 2-Substituted-2-(Dimethoxyphosphoryl)-Pyrrolidines from Substituted *tert*-Butyl 4-Oxobutylcarbamates and Trimethyl Phosphite

Zhao-Dan Chen, Wen-Ke Xu, Jia-Ming Guo, Ling Chen, Bang-Guo Wei,* Chang-Mei Si,* and Guo-Qiang Lin



ABSTRACT: A novel approach to 2-substituted-2-(dimethoxyphosphoryl)-pyrrolidines 7a-7o and 9a-9r has been developed, which features a TMSOTf-mediated one-pot intramolecular cyclization and phosphonylation of substituted *tert*-butyl 4-oxobutylcarbamates. The major advantages of this method include simple operation under mild reaction conditions, the use of cheap Lewis acid, and good to excellent yields with high diastereoselectivities (*dr* up to 99:1).

INTRODUCTION

 α -Aminophosphonic acids and their derivatives, classic isosteres of α -amino acids, have attracted great interest in organic and medicinal chemistry during the past few decades.¹ Such functional analogues of natural and unnatural α -amino acids have been widely used in agrochemicals² and medicines,³ such as antibacterial agents,⁴ antifungal agents,^{2a,5} antiviral agents,⁶ antibiotics,⁷ enzyme inhibitors,^{3a,8} and antitumor agents.⁹ In addition to the usual application as important synthetic intermediates in organic synthesis,¹⁰ they could also serve as probes in biology. Some typical examples include alafosfalin (an antibacterial agent) **1**,¹¹ K-26 (an ACE inhibitor) **2**,¹² MCR5 (a neuroprotective agent) **4**¹³ and radical probe **3**¹⁴ (Figure 1).

In the past few decades, tremendous efforts have been made to establish a new methodology for the syntheses of α -amino phosphonic acids and their derivatives.¹⁵⁻²⁰ One common approach was the three-component reaction of aldehydes (or ketones), primary amines, and phosphite (or phosphoric acid).¹⁹ A direct transformation of amides to phosphonates was also achieved through a reductive process,^{1b,20} which was further developed to prepare chiral α -amino phosphonates through asymmetric catalysis. In addition, Lewis acids²¹ or transition metal complexes²² could mediate the formation of acyliminium ions and its subsequent reaction with trimethyl phosphite to generate α -amino phosphonates (Figure 2, a). As for the preparation of piperidine α -tertiary amino phosphonates and their derivatives, two general approaches were often used, including the diethyl phosphite addition to readily available cyclic imines, and the Vilsmeier-Haack reaction of



Figure 1. Several useful compounds containing α -aminophosphonic acid moiety.

lactams with triethyl phosphite prompted by phosphoryl chloride.²³ For example, a direct method to the heterocyclic α -tertiary amine phosphonates from the alkenyl ketones has

Received: April 22, 2021





Figure 2. Our strategy to access 2-substituted-2-(dimethoxyphos-phoryl)-pyrrolidines.

been also achieved; however, this transformation need three steps (Figure 2, b).²⁴ In addition, an amine containing alkynyl bond compound has been converted to piperidine α -tertiary amino phosphonates and their derivatives through the Cp2TiMe2 prompted intramolecular hydroamination and followed phosphorylation process, but the intramolecular hydroamination needs 72 h (Figure 2, c).²⁵ Similarly, the alkyne amination/phosphorylation catalyzed by copper converted the secondary aminoalkynes to various cyclic α aminophosphonate derivatives (Figure 2, d).²⁶ δ -Amino α diazo β -ketophosphonate has also been converted to 3-oxo pyrrolidine phosphonate via an intramolecular metal carbenoid N–H insertion (Figure 2, e).²⁷ On the basis of our continuous efforts in establishment of azaheterocyclic building blocks,²⁸ we envisioned that the addition-phosphates of the carbonyl containing amides could occur. Herein we present this effective approach to 2-substituted-2-(dimethoxyphosphoryl)-pyrrolidines through the intramolecular condensation and phosphatization process (Figure 2, f).

RESULTS AND DISCUSSION

Our investigation started with the reaction of trimethyl phosphite 6 with *tert*-butyl 4-oxo-4-phenylbutylcarbamate 5a, which was prepared according to the known procedure (see the Supporting Information).²⁹ First, various metal salts including $Sc(OTf)_3$, $Yb(OTf)_3$, $In(OTf)_3$, $Cu(OTf)_2$, and

 $Cu(NTf_2)_2$ were examined, only trace amount of products were observed, and the starting material **5a** was almost intact (Table 1, entries 1–5). CuBr₂ could not promote this reaction

Table 1. Optimization of Reaction Conditions

Boc N H	Ph O	P(OMe) ₃ - s	LA solvent N B	Ph OMe P oc 0
	5a	6	7	a
entry ^a	Lewis acid (equiv)	solvent	T (°C)	yield (%) ^b
1	$Sc(OTf)_{3}$ (0.2)	DCM	-45 to rt	trace
2	$Yb(OTf)_{3}(0.2)$	DCM	-45 to rt	trace
3	$In(OTf)_{3}$ (0.2)	DCM	-45 to rt	trace
4	$Cu(OTf)_2$ (0.2)	DCM	-45 to rt	trace
5	$Cu(NTf_2)_2$ (0.2)	DCM	-45 to rt	trace
6	$CuBr_2$ (0.2)	DCM	-45 to rt	0
7	$B(C_6F_5)_3$ (0.2)	DCM	-45	23
8	$B(C_6F_5)_3(0.5)$	DCM	-45	35
9	TMSOTf (1.0)	DCM	-45	37
10	TMSOTf (1.5)	DCM	-45	64
11	TMSOTf (2.0)	DCM	-45	61
12	TMSOTf (1.5)	DCM	-45 to rt	53
13	TMSOTf (1.5)	DCM	-78	46
14	$BF_3 \cdot Et_2O(1.5)$	DCM	-45	51
15	$TiCl_{4}$ (1.5)	DCM	-45	47
16	TMSOTf (1.5)	THF	-45	44
17	TMSOTf (1.5)	PhMe	-45	38
18	TMSOTf (1.5)	DCE	-45	56

^{*a*}The reactions were performed with **5a** (0.5 mmol), $P(OMe)_3 6$ (0.6 mmol) and Lewis acid in dry solvent (2 mL) at assigned reaction temperature for 2 h. ^{*b*}Isolated yield.

at all, and no desired product was observed (Table 1, entry 6). When $B(C_6F_5)_3$ was used, the desired product 7a was obtained in 23% yield (Table 1, entry 7). It should be noted that the yield of 7a could be improved to 35% when 0.5 equiv of $B(C_6F_5)_3$ was used (Table 1, entry 8). Then, we turned to the application of stronger Lewis acids for this transformation, and TMSOTf proved to be a good choice. The experiments with different ratios of TMSOTf demonstrated the reaction and gave the best yield when 1.5 equiv of TMSOTf was used (Table 1, entries 9-11). In addition, neither higher temperature (-45 to rt) nor lower temperature (-78 °C) was beneficial for the yield of this one-pot process (Table 1, entries 12-13). Other Lewis acids, $BF_3 \cdot Et_2O$ and $TiCl_4$, were also examined, but they did not perform as well as TMSOTf (Table 1, entries 14-15). Finally, different solvents, such as THF, PhMe, and DCE, were also screened, and all of them could afford the desired product, albeit with lower yields. (Table 1, entries 16-18).

Next, we turned our attention to investigate the scope and limitation of this ring forming phosphorylation (Scheme 1). First, five *para*- or *meta* substituted phenyl ketones 5a-5e were examined, and the *para* substituted substrates 7c and 7d showed slightly higher yields than *meta* substituted 7b and 7e. Aliphatic ketones 5f-5h also worked well under the optimal reaction conditions, and the chain length of alkyl groups dramatically affected the yields of 7f-7h. Notably, alkynyl ketones 5k-5n could afford the desired products 7k-7n in 72-84% yields. Pyridinyl substituent was tolerated in this reaction, and the alkynone substrate 5o could lead to the

Scheme 1. Reactions of Substituted tert-Butyl 4-Oxobutylcarbamates with Trimethyl Phosphite a,b



^aThe reactions were performed with carbamates 5a-5p (0.5 mmol), P(OMe)₃ 6 (0.6 mmol), and TMSOTf (0.75 mmol) in dry DCM (2 mL) at -45 °C for 2 h. ^bIsolated yield.

desired 70 in 52% yield. Although the allyl substituted ketone Si gave the corresponding product 7i in 34% yield, the reaction of benzyl substituted ketone Sj could produce the desired 7j in 93% yield. To our disappointment, the efforts to prepare similar piperidin-2-yl phosphonate 7p turned out to be fruitless. The chemical structures of 7a-7o were unambiguously assigned according to X-ray crystallographic analysis of compound 7j (see the Supporting Information).

Then, we extended the reaction to chiral ketone substrates 8a-8r, which were prepared according to the known procedure (see the Supporting Information).²⁴ As shown in Scheme 2, all reactions proceeded well, and lower reaction temperature (-78 °C) was required for high diastereoselectivities (see the Supporting Information). First, when (S)-tertbutyl 3-(tert-butyldimethylsilyloxy)-4-oxohex-5-ynylcarbamate 8a was examined, the desired 9a was obtained in 82% yield with excellent diastereoselectivity (dr > 99:1). Other chiral alkynyl ketone substrates 8b-8d also afforded the desired 9b-9d in 73–80% yields with outstanding diastereoselectivities (dr > 99:1). Chiral aliphatic ketones 8e-8h were also screened, and the desired 9e-9h were generated in moderate yields with excellent diastereoselectivities (dr > 99:1). It is worth mentioning that isopropyl ketone substrate 8i led to the desired 9i in 55% yield with low diastereoselectivity (dr =74:26). As a matter of fact, aryl ketone substrates 8j-8o also resulted in the desired products 9j-90 with low diastereoselectivities (dr from 65:35 to 87:13) despite the relatively Scheme 2. Reactions of Chiral Substituted tert-Butyl 4-Oxobutylcarbamates with Trimethyl Phosphite a,b



^aThe reactions were performed with carbamates 8a-8r (0.5 mmol) P(OMe)₃ 6 (0.6 mmol), and TMSOTf (0.75 mmol) in dry DCM (2 mL) at -78 °C for 2 h. ^bIsolated yield.

excellent yields (>79%). Although the benzyl and allyl ketone substrates 8p-8q and 8r gave the corresponding 9p-9q and 9r in moderate yields, excellent diastereoselectivities were achieved (dr > 99:1). The chemical structures and stereo-chemistry of the products 9a-9r were unambiguously assigned by X-ray crystallographic analysis of compounds 9a and 9j (see the Supporting Information).

A possible mechanism for this one-pot approach to α alkylated pyrrolidin-2-yl phosphonates is presented in Figure 3.^{19i,22c,30,31} Under Lewis acid condition, the carbonyl group in 8a–8r were activated to form Int-1, which experienced an intramolecular nucleophilic addition to give Int-2. Upon the cleavage of OTMS group, a key iminium intermediate Int-3

pubs.acs.org/joc



Figure 3. Possible mechanism of this approach.

was generated, which could subsequently react with trimethyl phosphite to give the desired phosphonates 9a-9r. To explain the diastereoselectivities for this transformation, we speculate that the stable conformer Int-3b allowed the attack of trimethyl phosphite predominately from one side, forming the desired diastereomers 9a-9r.

CONCLUSIONS

In summary, we have established a novel and practical approach for the preparation of α -alkylated pyrrolidin-2-yl phosphonates, through a one-pot intramolecular cyclization and phosphorylation process, from substituted *tert*-butyl 4-oxobutylcarbamates. A series of products 7a-7o were conveniently prepared in moderate to good yields. On the basis of this efficient methodology, several chiral phosphonates 9a-9r could be obtained with excellent diastereoselectivities (*dr* up to 99:1). Moreover, the operation of this one-pot transformation is very simple, using a cheap Lewis acid under mild reaction conditions. Further applications of this method in pharmaceutical chemistry are currently underway in our laboratory.

EXPERIMENTAL SECTION

General Considerations. DCM was distilled from phosphoric anhydride. Reactions were monitored by thin layer chromatography (TLC) on glass plates coated with silica gel with a fluorescent indicator. Flash chromatography was performed on silica gel (300–400) with petroleum/EtOAc as eluent. Optical rotations were measured on a polarimeter with a sodium lamp. HRMS were measured on a LCMS-IT-TOF or LTQ-Orbitrap-XL apparatus. IR spectra were recorded using film on a Fourier Transform Infrared Spectrometer. NMR spectra were recorded at 100, 162, or 400 MHz, and chemical shifts are reported in δ (ppm) referenced to an internal TMS standard for ¹H NMR and CDCl₃ (77.16 ppm) for ¹³C{¹H} NMR.

General Procedure for the Synthesis of 5a–5o and 8a–8r. To a stirred solution of N-Boc-2-pyrrolidinone³² or (S)-tert-butyl 3-(tert-butyldimethylsilyloxy)-2-oxopyrrolidine-1-carboxylate³³ (2.0 mmol) in anhydrous THF (8 mL) was added Grignard reagent at -78 °C under argon atmosphere. After stirring for 2 h, the mixture was quenched with an aqueous solution of saturated NH₄Cl (5 mL), and extracted with EtOAc (15 mL \times 3). The combined organic layers were washed with brine and dried over Na₂SO₄. Filtered and concentrated, the residue was purified by flash chromatography on silica gel (petroleum ether/ethyl acetate = 8:1) to give 5a-5o and 8a-8r.

General Procedure for the Synthesis of 7a–7o. Carbamates 5a-5o (0.5 mmol) were dissolved in dry DCM (2 mL) under argon atmosphere. P(OMe)₃ (0.6 mmol) and TMSOTf (0.75 mmol) were added at -45 °C subsequently. After stirring for 2 h at -45 °C, the mixture was quenched with an aqueous solution of saturated NaHCO₃ (5 mL), and extracted with EtOAc (10 mL × 3). The combined organic layers were washed with brine and dried over Na₂SO₄. Filtered and concentrated, the residue was purified by flash chromatography on silica gel (petroleum ether/ethyl acetate = 2:1) to give 7a–7o.

General Procedure for the Synthesis of 9a–9r. Carbamates 8a–8r (0.5 mmol) were dissolved in dry DCM (2 mL) under argon atmosphere. P(OMe)₃ (0.6 mmol) and TMSOTf (0.75 mmol) were added at -78 °C subsequently. After stirring for 2 h at -78 °C, the mixture was quenched with an aqueous solution of saturated NaHCO₃ (5 mL), and extracted with EtOAc (10 mL × 3). The combined organic layers were washed with brine and dried over Na₂SO₄. Filtered and concentrated, the residue was purified by flash chromatography on silica gel (petroleum ether/ethyl acetate = 2:1) to give 9a–9r.

tert-Butyl 4-oxo-4-phenylbutylcarbamate (5a).³⁴ The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). White solid (432 mg, 82%). mp 85–86 °C [lit.³⁴ mp 80–82 °C]; IR (film) ν_{max} 3372, 1681, 1515, 1445, 1365, 1247, 1155, 739, 614 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.02–7.93 (m, 2H), 7.63–7.40 (m, 3H), 4.70 (s, 1H), 3.32–3.15 (m, 2H), 3.09–3.00 (m, 2H), 2.03–1.87 (m, 2H), 1.44 (s, 9H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 199.9, 156.2, 136.9, 133.2, 128.7, 128.2, 79.3, 40.3, 35.9, 28.5, 24.7 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₅H₂₁NO₃Na⁺ 286.1414, found 286.1413.

tert-Butyl 4-oxo-4-m-tolylbutylcarbamate (**5b**).³⁴ The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). White solid (477 mg, 86%). mp 47–48 °C [lit.³⁴ mp 58–60 °C]; IR (film) ν_{max} 3361, 2975, 1682, 1517, 1366, 1249, 1164, 782 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.87–7.82 (m, 2H), 7.41–7.30 (m, 2H), 4.74 (s, 1H), 3.28–3.17 (m, 2H), 3.05–2.96 (m, 2H), 2.42 (s, 3H), 1.98–1.90 (m, 2H), 1.44 (s, 9H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 200.1, 156.2, 138.5, 137.0, 133.9, 128.7, 128.6, 125.4, 79.2, 40.3, 35.9, 28.5, 24.7, 21.4 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₆H₂₃NO₃Na⁺ 300.1576, found 300.1561.

tert-Butyl 4-oxo-4-p-tolylbutylcarbamate (5c).³⁴ The title compound was purified by column chromatography (petroleum ether/ ethyl acetate = 8:1, R_f = 0.3). White solid (494 mg, 89%). mp 86–87 °C [lit.³⁴ mp 92–94 °C]; IR (film) ν_{max} 3394, 2983, 1706, 1669, 1512, 1292, 1167, 818, 565 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.87–7.82 (m, 2H), 7.28–7.22 (m, 2H), 4.72 (s, 1H), 3.25–3.14 (m, 2H), 3.02–2.97 (m, 2H), 2.41 (s, 3H), 1.96–1.87 (m, 2H), 1.42 (s, 9H) ppm; ¹³C{¹H} NMR (400 MHz, CDCl₃) δ 199.5, 156.2, 143.9, 134.5, 129.4, 128.3, 79.2, 40.3, 35.8, 28.5, 24.7, 21.7 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₆H₂₃NO₃Na⁺ 300.1570, found 300.1568.

tert-Butyl 4-(4-methoxyphenyl)-4-oxobutylcarbamate (5d).³⁴ The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). White solid (528 mg, 90%). mp 82–83 °C [lit.³⁴ mp 80–82 °C]; IR (film) ν_{max} 3357, 2971, 1675, 1594, 1509, 1362, 1252, 1160, 837 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.98–7.92 (m, 2H), 6.97–6.91 (m, 2H), 4.74 (s, 1H), 3.88 (s, 3H), 3.29–3.17 (m, 2H), 3.02–2.91 (m, 2H), 1.97– 1.86 (m, 2H), 1.44 (s, 9H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 198.5, 163.6, 156.2, 130.4, 130.0, 113.8, 79.2, 55.6, 40.3, 35.5, 28.5, 24.8 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₆H₂₃NO₄Na⁺ 316.1519, found 316.1520.

tert-Butyl 4-(3-chlorophenyl)-4-oxobutylcarbamate (5e).³⁴ The title compound was purified by column chromatography (petroleum

ether/ethyl acetate = 8:1, R_f = 0.3). White solid (476 mg, 80%). mp 73–74 °C [lit.³⁴ mp 80–82 °C]; IR (film) ν_{max} 3375, 2982, 1689, 1513, 1362, 1249, 1164, 782 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.94–7.89 (m, 1H), 7.85–7.80 (m, 1H), 7.55–7.49 (m, 1H), 7.43– 7.36 (m, 1H), 4.69 (s, 1H), 3.25–3.19 (m, 2H), 3.02–2.98 (m, 2H), 1.96–1.90 (m, 2H), 1.42 (s, 9H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 198.5, 156.2, 138.5, 135.1, 133.1, 130.1, 128.3, 126.3, 79.4, 40.1, 35.9, 285, 24.6 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₅H₂₀ClNO₃Na⁺ 320.1024, found 320.1028.

tert-Butyl 4-oxopentylcarbamate (**5f**).³⁵ The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). Light yellow oil (298 mg, 74%). IR (film) ν_{max} 3368, 2968, 1708, 1520, 13628, 1245, 1164, 977 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.76 (s, 1H), 3.16–3.07 (m, 2H), 2.49–2.39 (m, 4H), 1.82–1.72 (m, 2H), 1.43 (s, 9H), 1.10–1.01 (m, 3H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 211.2, 156.1, 79.1, 39.4 (40.0), 36.0, 28.4, 24.2, 7.8 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₀H₁₉NO₃Na⁺ 224.1257, found 224.1263.

tert-Butyl 4-oxooctylcarbamate (**5g**).³⁶ The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). Yellow oil (263 mg, 54%). IR (film) ν_{max} 3372, 2971, 1715, 1520, 1370, 1252, 1175, 1047 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.65 (s, 1H), 3.16–3.04 (m, 2H), 2.49–2.35 (m, 4H), 1.80–1.71 (m, 2H), 1.57–1.51 (m, 2H), 1.43 (s, 9H), 1.34–1.25 (m, 2H), 0.94–0.85 (m, 3H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 210.9, 156.2, 79.2, 42.7, 40.2, 39.9, 28.5, 26.0, 24.2, 22.4, 13.9 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₃H₂₅NO₃Na⁺ 266.1727, found 266.1724.

tert-Butyl 4-oxononylcarbamate (*5h*). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). White solid (375 mg, 87%). mp 30–31 °C; IR (film) ν_{max} 3369, 2933, 1707, 1519, 1368, 1245, 1175, 781 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.74 (*s*, 1H), 3.19–3.00 (m, 2H), 2.50–2.37 (m, 4H), 1.82–1.69 (m, 2H), 1.63–1.50 (m, 2H), 1.44 (*s*, 9H), 1.35–1.21 (m, 4H), 0.92–0.81 (m, 3H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 211.0, 156.1, 79.2, 42.9, 40.1, 39.9, 31.5, 28.5, 24.1, 23.6, 22.5, 14.0 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₁H₂₁NO₃Na⁺ 238.1414, found 238.1418.

tert-Butyl 4-oxohept-6-enylcarbamate (*5i*). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). Colorless oil (291 mg, 64%). IR (film) ν_{max} 3364, 2975, 1708, 1520, 1362, 1249, 1171, 1039 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 6.01–5.82 (m, 1H), 5.24–5.08 (m, 2H), 4.71 (s, 1H), 3.21–3.15 (m, 2H), 3.14–3.06 (m, 2H), 2.52–2.47 (m, 2H), 1.79–1.71 (m, 2H), 1.44 (s, 9H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 208.4, 156.2, 130.6, 119.0, 79.3, 47.9, 40.0, 39.4, 28.4, 24.0 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₂H₂₁NO₃Na⁺ 250.1414, found 250.1417.

tert-Butyl 4-oxo-5-phenylpentylcarbamate (5j). The title compound was purified by column chromatography (petroleum ether/ ethyl acetate = 8:1, R_f = 0.3). White solid (474 mg, 90%). mp 46–47 °C; IR (film) ν_{max} 3364, 2979, 1708, 1520, 1366, 1252, 1164, 701 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.39–7.16 (m, 5H), 4.57 (s, 1H), 3.71 (s, 2H), 3.16–3.00 (m, 2H), 1.78–1.72 (m, 2H), 1.45 (s, 9H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 208.0, 156.1, 134.3, 129.5, 128.9, 127.2, 79.3, 50.4, 40.0, 39.1, 28.5, 24.2 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₅H₂₁NO₃Na⁺ 286.1414, found 286.1413.

tert-Butyl 4-oxohex-5-ynylcarbamate (5k).³⁷ The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). Yellow solid (262 mg, 62%). mp 65–66 °C [lit.³⁷ mp 68–70 °C]; IR (film) ν_{max} 3357, 2975, 2090, 1678, 1517, 1362, 1252, 1164 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.71 (s, 1H), 3.27 (s, 1H), 3.20–3.10 (m, 2H), 2.70–2.61 (m, 2H), 1.90–1.82 (m, 2H), 1.44 (s, 9H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 186.7, 156.1, 81.4, 79.4, 79.0, 42.8, 39.8, 28.5, 24.2 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₁H₁₇NO₃Na⁺ 234.1101, found 234.1101.

tert-Butyl 4-oxo-6-phenylhex-5-ynylcarbamate (51).³⁸ The title compound was purified by column chromatography (petroleum

ether/ethyl acetate = 8:1, R_f = 0.3). White solid (431 mg, 75%). mp 62–63 °C [lit.³⁸ mp 69.5–70.5 °C]; IR (film) ν_{max} 3368, 2975, 2204, 1671, 1513, 1362, 1249, 1171, 753 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.59–7.51 (m, 2H), 7.48–7.31 (m, 3H), 4.70 (s, 1H), 3.24–3.13 (m, 2H), 2.74–2.68 (m, 2H), 1.93–1.84 (m, 2H), 1.45 (s, 9H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 187.2, 156.1, 133.1, 130.8, 128.7, 119.9, 91.1, 87.8, 79.3, 42.8, 39.9, 28.5, 24.5 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₇H₂₁NO₃Na⁺ 310.1414, found 310.1415.

tert-Butyl 4-oxo-6-p-tolylhex-5-ynylcarbamate (5m). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). White solid (428 mg, 71%). mp 75–77 °C; IR (film) ν_{max} 2975, 2193, 1667, 1509, 1362, 1168, 819 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.52–7.44 (m, 2H), 7.24–7.15 (m, 2H), 4.67 (s, 1H), 3.26–3.12 (m, 2H), 2.79–2.66 (m, 2H), 2.40 (s, 3H), 1.97–1.84 (m, 2H), 1.46 (s, 9H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 187.4, 156.2, 141.7, 133.3, 129.6, 116.9, 91.9, 87.8, 79.5, 42.9, 40.0, 28.5, 24.6, 21.9 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₈H₂₃NO₃Na⁺ 324.1570, found 324.1567.

tert-Butyl 6-(4-chlorophenyl)-4-oxohex-5-ynylcarbamate (5n).³⁸ The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). White solid (541 mg, 84%). mp 104–105 °C [lit.³⁸ mp 104.3–105 °C]; IR (film) ν_{max} 3350, 2982, 2200, 1678, 1517, 1362, 1252, 1164, 826 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.54–7.44 (m, 2H), 7.39–7.31 (m, 2H), 4.71 (s, 1H), 3.24–3.13 (m, 2H), 2.73–2.67 (m, 2H), 1.92–1.85 (m, 2H), 1.44 (s, 9H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 187.0, 156.1, 137.3, 134.3, 129.2, 118.5, 89.6, 88.5, 79.4, 42.8, 39.9, 28.5, 24.5 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₇H₂₀ClNO₃Na⁺ 344.1024, found 344.1025.

tert-Butyl 4-oxo-6-(pyridin-3-yl)hex-5-ynylcarbamate (**50**).³⁸ The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). Light yellow solid (231 mg, 40%). mp 79–80 °C [lit.³⁸ mp 79.3–80 °C]; IR (film) ν_{max} 2982, 2204, 1678, 1517, 1366, 1274, 1168, 701 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.82–8.76 (m, 1H), 8.70–8.63 (m, 1H), 7.91–7.80 (m, 1H), 7.39–7.30 (m, 1H), 4.71 (s, 1H), 3.24–3.15 (m, 2H), 2.79–2.72 (m, 2H), 1.96–1.88 (m, 2H), 1.45 (s, 9H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 186.8, 156.1, 153.4, 150.9, 140.0, 123.4, 117.4, 90.3, 87.0, 79.4, 42.8, 39.9, 28.5, 24.5 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₆H₂₀N₂O₃Na⁺ 311.1372, found 311.1371.

tert-Butyl 2-(dimethoxyphosphoryl)-2-phenylpyrrolidine-1-carboxylate (**7a**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, R_f = 0.3). Colorless oil (114 mg, 64%). IR (film) ν_{max} 2913, 2850, 1700, 1384, 1252, 1164, 1028, 756 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 7.44–7.20 (m, 5H), 3.89–3.70 (m, 6H), 3.70–3.52 (m, 2H), 2.95– 2.66 (m, 1H), 2.31–2.18 (m, 1H), 1.92–1.73 (m, 1H), 1.69–1.55 (m, 1H), 1.53–1.20 (m, 9H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃, rotamers) δ 154.3, 140.0 (d, J = 7.3 Hz) (141.1), 128.2 (127.9), 127.9, 125.8 (125.9), 80.0 (80.6), 69.0 (d, J = 159.8 Hz) (68.9), 54.4 (d, J = 7.4 Hz) (54.3), 52.7 (d, J = 7.4 Hz) (52.5), 48.9 (d, J = 4.4 Hz) (49.4), 41.4 (43.3), 28.5 (28.1), 22.3 (d, J = 7.3 Hz) (21.5) ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 29.0 (27.5) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₇H₂₆NO₅PNa⁺ 378.1441, found 378.1436.

tert-Butyl 2-(dimethoxyphosphoryl)-2-m-tolylpyrrolidine-1-carboxylate (**7b**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, R_f = 0.3). Colorless oil (98 mg, 53%). IR (film) ν_{max} 2953, 1697, 1392, 1256, 1168, 1036, 756, 565 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 7.28–7.03 (m, 4H), 3.87–3.55 (m, 8H), 2.92–2.64 (m, 1H), 2.35 (s, 3H), 2.29–2.17 (m, 1H), 1.89–1.75 (m, 1H), 1.70–1.58 (m, 1H), 1.55–1.28 (m, 9H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃, rotamers) δ 154.2 (154.5), 139.9 (d, J = 7.4 Hz) (140.9), 137.6 (137.4), 128.1, 127.8 (127.7), 126.5, 123.0 (d, J = 3.5 Hz), 80.0 (80.6), 69.0 (d, J = 159.9 Hz), 54.4 (d, J = 6.1 Hz), 52.9 (d, J = 7.4 Hz) (52.5), 49.0 (d, J = 3.3 Hz) (49.5), 41.4 (43.3), 28.6 (28.2), 22.3 (d, J = 8.8 Hz), 21.9 (21.7) ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 29.1 (27.6) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₈H₂₈NO₅PNa⁺ 392.1597, found 392.1591.

tert-Butyl 2-(dimethoxyphosphoryl)-2-p-tolylpyrrolidine-1-carboxylate (7c). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, R_f = 0.3). Yellow oil (129 mg, 70%). IR (film) ν_{max} 2957, 1708, 1392, 1256, 1164, 1036, 811, 749, 584 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 7.31–7.24 (m, 2H), 7.16–7.09 (m, 2H), 3.83–3.72 (m, 6H), 3.71–3.53 (m, 2H), 2.91–2.61 (m, 1H), 2.33 (s, 3H), 2.27– 2.19 (m, 1H), 1.88–1.74 (m, 1H), 1.70–1.57 (m, 1H), 1.55–1.28 (m, 9H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃, rotamers) δ 154.3, 137.0 (d, *J* = 6.8 Hz) (137.9), 136.6, 128.9 (128.6), 125.8 (d, *J* = 4.3 Hz), 80.0 (80.7), 68.9 (d, *J* = 160.0 Hz), 54.5 (d, *J* = 5.5 Hz) (54.4), 52.7 (d, *J* = 6.1 Hz), 41.4 (43.4), 28.6 (28.2), 22.3 (d, *J* = 8.7 Hz) (21.5), 21.0 ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 26.8 (25.2) ppm; HRMS (ESI-Orbitrap) *m*/*z* [M + Na]⁺ calcd for C₁₈H₂₈NO₅PNa⁺ 392.1597, found 392.1593.

tert-Butyl 2-(dimethoxyphosphoryl)-2-(4-methoxyphenyl)pyrrolidine-1-carboxylate (7d). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, R_f = 0.3). Colorless oil (145 mg, 75%). IR (film) ν_{max} 2953, 1700, 1509, 1392, 1252, 1179, 1036, 822 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 7.35–7.26 (m, 2H), 6.88–6.78 (m, 2H), 3.84–3.78 (m, 3H), 3.78–3.69 (m, 6H), 3.68–3.48 (m, 2H), 2.96–2.55 (m, 1H), 2.26–2.19 (m, 1H), 1.88–1.76 (m, 1H), 1.68–1.56 (m, 1H), 1.53– 1.31 (m, 9H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃, rotamers) δ 158.5, 154.3, 131.8 (d, *J* = 5.5 Hz) (132.8), 127.1 (d, *J* = 4.4 Hz), 113.6 (113.2), 79.9 (80.7), 68.5 (d, *J* = 160.2 Hz), 54.5 (d, *J* = 6.6 Hz), 52.7 (d, *J* = 7.2 Hz), 48.9 (49.4), 41.3 (43.3), 28.6 (28.2), 22.2 (d, *J* = 8.9 Hz) (21.4) ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 29.2 (27.5) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₈H₂₈NO₆PNa⁺ 408.1547, found 408.1542.

tert-Butyl 2-(3-chlorophenyl)-2-(dimethoxyphosphoryl)pyrrolidine-1-carboxylate (**7e**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, R_f = 0.3). Yellow oil (134 mg, 69%). IR (film) ν_{max} 3453, 2957, 1697, 1385, 1256, 1028, 760, 562 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 7.43–7.17 (m, 4H), 3.90–3.65 (m, 7H), 3.64–3.54 (m, 1H), 2.96–2.67 (m, 1H), 2.30–2.12 (m, 1H), 1.91–1.76 (m, 1H), 1.73–1.57 (m, 1H), 1.55–1.27 (m, 9H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃, rotamers) δ 154.2, 142.5 (d, *J* = 3.5 Hz) (143.3), 134.2, 129.5 (129.3), 127.3, 126.3, 124.2, 80.4 (81.0), 68.8 (d, *J* = 161.0 Hz) (68.6), 54.6 (d, *J* = 6.8 Hz), 52.8 (d, *J* = 7.2 Hz), 49.0 (49.5), 41.5 (43.3), 28.6 (28.2), 22.4 (d, *J* = 8.2 Hz) (21.7) ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 28.4 (27.0) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₇H₂₅CINO₅PNa⁺ 412.1051, found 412.1052.

tert-Butyl 2-(dimethoxyphosphoryl)-2-methylpyrrolidine-1-carboxylate (**7f**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, R_f = 0.3). Colorless oil (95 mg, 65%). IR (film) ν_{max} 2969, 1698, 1387, 1244, 1156, 1111, 1031, 815 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 3.86–3.70 (m, 6H), 3.61–3.41 (m, 2H), 2.59–2.45 (m, 1H), 2.02–1.91 (m, 1H), 1.87–1.71 (m, 2H), 1.63–1.57 (d, J = 3.7 Hz, 3H), 1.47 (s, 9H) ppm; ¹³C{¹H} NMR (100 MHz, DMSO- d_6 , Temp = 75 °C) δ 152.7, 78.5, 60.6 (d, J = 156.4 Hz), 52.3 (d, J = 7.0 Hz), 52.1 (d, J = 7.5 Hz), 48.3, 38.1, 27.8, 21.7 (d, J = 7.1 Hz) (20.9) ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 31.0 (30.1) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₂H₂₄NO₅PNa⁺ 316.1284, found 316.1279.

tert-Butyl 2-butyl-2-(dimethoxyphosphoryl)pyrrolidine-1-carboxylate (**7g**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, R_f = 0.3). Colorless oil (75 mg, 45%). IR (film) ν_{max} 2960, 1697, 1385, 1249, 1171, 1028, 819, 569 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 3.85–3.66 (m, 6H), 3.57–3.37 (m, 2H), 2.51–2.28 (m, 2H), 2.04– 1.94 (m, 2H), 1.80–1.65 (m, 2H), 1.52–1.43 (m, 9H), 1.35–1.11 (m, 4H), 0.95–0.86 (m, 3H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃, rotamers) δ 153.6 (154.3), 79.3 (80.3), 64.9 (d, *J* = 154.1 Hz) (64.5), 53.5 (d, *J* = 5.7 Hz) (53.3), 52.4 (d, *J* = 6.2 Hz) (52.6), 49.4, 34.4 (35.6), 32.3 (33.0), 28.5, 25.3 (d, J = 8.9 Hz) (24.8), 22.9 (22.6), 21.9, 14.2 ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 31.3 (30.3) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₅H₃₀NO₅PNa⁺ 358.1754, found 358.1752.

tert-Butyl 2-(dimethoxyphosphoryl)-2-pentylpyrrolidine-1-carboxylate (7h). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, R_f = 0.3). Colorless oil (70 mg, 40%). IR (film) ν_{max} 2951, 1697, 1382, 1247, 1170, 1032, 820, 565 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 3.86–3.66 (m, 6H), 3.58–3.30 (m, 2H), 2.49–2.29 (m, 2H), 2.02– 1.90 (m, 2H), 1.78–1.67 (m, 2H), 1.53–1.42 (m, 9H), 1.33–1.10 (m, 6H), 0.94–0.78 (m, 3H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃, rotamers) δ 153.6 (154.3), 79.3 (80.3), 64.8 (d, *J* = 154.2 Hz) (64.6), 53.6 (d, *J* = 6.5 Hz) (53.4), 52.4 (d, *J* = 7.0 Hz) (52.6), 49.5 (d, *J* = 8.3 Hz), 35.6, 34.4, 32.4 (d, *J* = 6.2 Hz) (33.2), 32.0 (32.2), 28.5, 22.7 (d, *J* = 10.9 Hz) (22.3), 21.9, 14.1 ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 31.3 (30.3) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₆H₃₂NO₅PNa⁺ 372.1910, found 372.1906.

tert-Butyl 2-allyl-2-(dimethoxyphosphoryl)pyrrolidine-1-carboxylate (7i). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, R_f = 0.3). Colorless oil (54 mg, 34%). IR (film) ν_{max} 2972, 1691, 1376, 1240, 1167, 1035, 822, 756 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 5.74–5.58 (m, 1H), 5.21–5.09 (m, 2H), 3.87–3.68 (m, 6H), 3.52–3.13 (m, 3H), 2.47–2.34 (m, 2H), 2.01–1.82 (m, 2H), 1.78–1.67 (m, 1H), 1.53–1.43 (m, 9H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃, rotamers) δ 154.1 (153.6), 132.5 (d, *J* = 11.4 Hz) (132.1), 119.7 (119.5), 79.5 (80.6), 64.2 (d, *J* = 144.0 Hz) (63.9), 53.7 (d, *J* = 5.9 Hz) (53.4), 52.4 (d, *J* = 6.9 Hz) (52.7), 49.4, 36.6 (d, *J* = 6.7 Hz) (37.6), 34.0 (35.3), 28.5, 22.4 (21.6) ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 30.4 (29.5) ppm; HRMS (ESI-Orbitrap) *m*/*z* [M + Na]⁺ calcd for C₁₄H₂₆NO₅PNa⁺ 342.1441, found 342.1442.

tert-Butyl 2-benzyl-2-(dimethoxyphosphoryl)pyrrolidine-1-carboxylate (7j). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, $R_f = 0.3$). White solid (172 mg, 93%). mp 108–109 °C; IR (film) ν_{max} 2975, 1693, 1392, 1249, 1160, 1058, 1024, 756 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) & 7.30-7.16 (m, 5H), 4.09-3.92 (m, 1H), 3.91-3.76 (m, 6H), 3.37-3.06 (m, 2H), 2.81-2.71 (m, 1H), 2.51-2.39 (m, 1H), 2.07–1.96 (m, 1H), 1.64–1.62 (m, 2H), 1.62–1.57 (m, 1H), 1.57–1.51 (m, 7H), 0.90–0.72 (m, 1H) ppm; $^{13}\mathrm{C}\{^{1}\mathrm{H}\}$ NMR (100 MHz, CDCl₃, rotamers) δ 154.1 (154.4), 136.6 (d, J = 15.0 Hz) (136.3), 130.9 (130.6), 128.2 (128.5), 126.7 (126.9), 79.7 (81.2), 65.2 (d, J = 155.0 Hz) (65.1), 54.0 (d, J = 6.8 Hz) (53.8), 52.4 (d, J = 7.8 Hz) (52.6), 49.2 (d, J = 2.5 Hz) (49.5), 36.9 (d, J = 8.9 Hz) (38.2), 33.9 (35.2), 28.6, 22.1 (d, J = 4.0 Hz) (21.4) ppm; ³¹P NMR (162 MHz, $CDCl_3$, rotamers) δ 31.4 (30.0) ppm; HRMS (ESI-Orbitrap) $m/z [M + Na]^+$ calcd for C₁₈H₂₈NO₅PNa⁺ 392.1597, found 392.1596.

tert-Butyl 2-(dimethoxyphosphoryl)-2-ethynylpyrrolidine-1-carboxylate (**7k**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, R_f = 0.3). Yellow solid (109 mg, 72%). mp 73–74 °C; IR (film) ν_{max} 3221, 2957, 1693, 1392, 1252, 1168, 1021, 573 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 3.91–3.80 (m, 6H), 3.68–3.57 (m, 1H), 3.49–3.40 (m, 1H), 2.77–2.64 (m, 1H), 2.58–2.53 (d, *J* = 4.8 Hz, 1H), 2.42–2.29 (m, 1H), 2.06–1.91 (m, 2H), 1.49 (s, 9H) ppm; ¹³C{¹H} NMR (100 MHz, DMSO- d_6 , Temp = 75 °C) δ 152.2, 81.1 (d, *J* = 4.4 Hz), 79.3, 75.2 (d, *J* = 9.3 Hz), 57.6, 55.9, 53.4, 53.5 (53.3), 47.7 (d, *J* = 2.5 Hz), 27.7, 22.0 (d, *J* = 3.8 Hz) ppm; ³¹P NMR (162 MHz, CDCl₃) δ 23.0 (2.4) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₃H₂₂NO₅PNa⁺ 326.1128, found 326.1127.

tert-Butyl 2-(dimethoxyphosphoryl)-2-(2-phenylethynyl)pyrrolidine-1-carboxylate (71). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, R_f = 0.3). Light yellow oil (159 mg, 84%). IR (film) ν_{max} 2977, 1685, 1590, 1385, 1249, 1165, 1026, 762 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.48–7.24 (m, 5H), 3.95–3.79 (m, 6H), 3.74–3.57 (m, 1H), 3.54– 3.46 (m, 1H), 2.89–2.65 (m, 1H), 2.51–2.37 (m, 1H), 2.09–1.98 (m, 2H), 1.51 (s, 9H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 153.6, 131.8, 128.5, 128.4, 122.7, 86.6 (d, J = 2.7 Hz), 85.4 (d, J = 9.3 Hz), 80.5, 58.9, 57.2, 54.5, 48.6, 40.8, 28.5, 23.1 ppm; ³¹P NMR (162 MHz, CDCl₃) δ 22.9 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₉H₂₆NO₅PNa⁺ 402.1441, found 402.1437.

tert-Butyl 2-(dimethoxyphosphoryl)-2-(2-p-tolylethynyl)pyrrolidine-1-carboxylate (7m). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, R_f = 0.3). Yellow oil (153 mg, 78%). IR (film) ν_{max} 3464, 2964, 1693, 1388, 1263, 1164, 1028, 808, 569 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.32–7.25 (m, 2H), 7.13–7.00 (m, 2H), 3.95–3.74 (m, 6H), 3.70– 3.53 (m, 1H), 3.50–3.37 (m, 1H), 2.84–2.64 (m, 1H), 2.47–2.36 (m, 1H), 2.29 (s, 3H), 2.05–1.85 (m, 2H), 1.46 (s, 9H) ppm; 1³C{¹H} NMR (100 MHz, CDCl₃) δ 153.4, 138.4, 131.5, 129.0, 119.5, 85.8 (d, *J* = 3.4 Hz), 85.3 (d, *J* = 9.3 Hz), 80.3, 58.8, 57.1, 54.3, 48.4, 40.6, 28.3, 22.8, 21.4 ppm; ³¹P NMR (162 MHz, CDCl₃) δ 20.5 ppm; HRMS (ESI-Orbitrap) *m*/*z* [M + Na]⁺ calcd for C₂₀H₂₈NO₅PNa⁺ 416.4036, found 416.4032.

tert-Butyl 2-(2-(4-chlorophenyl)ethynyl)-2-(dimethoxyphosphoryl)pyrrolidine-1-carboxylate (**7n**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, R_f = 0.3). Colorless oil (168 mg, 81%). IR (film) ν_{max} 2975, 1689, 1491, 1384, 1260, 1160, 1032, 837, 573 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.40–7.35 (m, 2H), 7.32–7.28 (m, 2H), 3.93–3.85 (m, 6H), 3.74–3.65 (m, 1H), 3.54–3.46 (m, 1H), 2.85–2.72 (m, 1H), 2.51–2.37 (m, 1H), 2.10–1.94 (m, 2H), 1.51 (s, 9H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 153.5, 134.6, 133.0, 128.7, 121.3, 87.7 (d, J = 3.5 Hz), 84.2 (d, J = 9.3 Hz), 80.5, 59.0, 57.2, 54.4, 48.6, 40.6, 28.5, 23.1 ppm; ³¹P NMR (162 MHz, CDCl₃), rotamers) δ 20.4 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₉H₂₅ClNO₅PNa⁺ 436.1051, found 436.1054.

tert-Butyl 2-(dimethoxyphosphoryl)-2-(2-(pyridin-3-yl)ethynyl)pyrrolidine-1-carboxylate (**70**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, R_f = 0.3). Yellow oil (99 mg, 52%). IR (film) ν_{max} 3464, 2953, 1686, 1388, 1252, 1164, 1024, 833, 576 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.69–8.64 (m, 1H), 8.57–8.50 (m, 1H), 7.77–7.70 (m, 1H), 7.29– 7.24 (m, 1H), 3.92–3.85 (m, 6H), 3.74–3.65 (m, 1H), 3.53–3.44 (m, 1H), 2.86–2.72 (m, 1H), 2.51–2.38 (m, 1H), 2.12–2.01 (m, 2H), 1.51 (s, 9H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 153.4, 152.4, 148.9, 138.7, 123.1, 120.0, 90.2 (d, *J* = 3.5 Hz), 82.0 (d, *J* = 9.4 Hz), 80.6, 58.9, 57.2, 54.4, 48.6, 40.5, 28.5, 23.2 ppm; ³¹P NMR (162 MHz, CDCl₃) δ 22.7 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₈H₂sN₂O₆PNa⁺ 403.1393, found 403.1394.

(S)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-oxohex-5-ynylcarbamate (**8a**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). Yellow oil (444 mg, 65%). [α]_D²⁴ -4.1 (c 2.00, CHCl₃); IR (film) ν_{max} 3221, 2957, 1693, 1392, 1252, 1168, 1021, 573 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 4.80 (s, 1H), 4.28-4.23 (m, 1H), 3.37 (s, 1H), 3.29-3.14 (m, 2H), 2.06-1.90 (m, 2H), 1.47-1.40 (m, 9H), 0.92-0.90 (m, 9H), 0.12-0.04 (m, 6H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃, rotamers) δ 189.0, 155.9, 82.6, 79.9 (79.3), 77.7, 43.9, 37.0, 33.9, 28.5, 25.8, 18.3, -4.6, -5.2 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₇H₃₁NO₄SiNa⁺ 364.1915, found 364.1916.

(S)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-oxo-6-phenylhex-5-ynylcarbamate (**8b**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). Yellow oil (342 mg, 50%). [α]_D²⁵ -39.2 (*c* 0.50, CHCl₃); IR (film) ν_{max} 2924, 2204, 1686, 1590, 1256, 1168, 833 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.63–7.58 (m, 2H), 7.50–7.37 (m, 3H), 4.93 (s, 1H), 4.41–4.33 (m, 1H), 3.38–3.24 (m, 2H), 1.44 (s, 9H), 0.98 (s, 9H), 0.16 (s, 3H), 0.12 (s, 3H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 189.7, 155.9, 133.3, 131.0, 128.8, 120.0, 94.8, 86.6, 79.2, 77.9, 37.2, 34.3, 28.5, 25.9, 18.3, -4.5, -5.1 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₇H₃₁NO₄SiNa⁺ 364.1915, found 364.1916.

(S)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-oxo-6-p-tolylhex-5ynylcarbamate (**8c**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, $R_f = 0.3$). Yellow oil (665 mg, 77%). $[\alpha]_{D}^{26}$ –51.4 (*c* 1.00, CHCl₃); IR (film) ν_{max} 3357, 2931, 2193, 1671, 1502, 1256, 1160, 833, 775 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.54–7.47 (m, 2H), 7.25–7.17 (m, 2H), 4.94 (s, 1H), 4.41–4.29 (m, 1H), 3.39–3.24 (m, 2H), 2.41 (s, 3H), 2.15–1.99 (m, 2H), 1.44 (s, 9H), 0.98 (s, 9H), 0.16 (s, 3H), 0.12 (s, 3H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 189.9, 155.9, 141.9, 133.4, 129.6, 116.9, 95.7, 86.5, 79.2, 77.9, 37.2, 34.3, 28.5, 25.9, 21.9, 18.4, –4.5, –5.1 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₂₄H₃₇NO₄SiNa⁺ 454.2384, found 454.2383.

(5)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-6-(4-chlorophenyl)-4-oxohex-5-ynylcarbamate (**8d**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). Yellow oil (756 mg, 84%). $[\alpha]_D^{2^7}$ –28.2 (*c* 0.50, CHCl₃); IR (film) ν_{max} 3376, 2924, 2200, 1711, 1495, 1256, 1146, 837, 775 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 7.58–7.48 (m, 2H), 7.42– 7.35 (m, 2H), 4.89 (s, 1H), 4.36–4.30 (m, 1H), 3.36–3.25 (m, 2H), 2.12–1.96 (m, 2H), 1.55–1.54 (m, 3H), 1.44–1.43 (m, 6H), 0.97– 0.92 (m, 9H), 0.15 (s, 3H), 0.12 (s, 3H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃, rotamers) δ 189.6, 155.9, 137.5, 134.4, 129.3, 118.5, 93.2, 87.2, 83.2 (79.3), 77.8 (71.8), 41.9, 37.1 (34.3), 28.5 (28.2), 25.9, 18.3, –4.5, –5.1 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₂₃H₃₄CINO₄SiNa⁺ 474.1838, found 474.1837.

(*S*)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-oxopentylcarbamate (*8e*). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). Colorless oil (364 mg, 55%). $[\alpha]_D^{25}$ -8.6 (*c* 1.00, CHCl₃); IR (film) ν_{max} 3357, 2927, 2854, 1715, 1513, 1252, 1171, 841, 778 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 4.83 (s, 1H), 4.12–4.05 (m, 1H), 3.26–3.11 (m, 2H), 2.66–2.47 (m, 2H), 2.11 (s, 3H), 1.93– 1.76 (m, 2H), 1.42 (s, 9H), 0.95–0.91 (m, 9H), 0.07 (s, 3H), 0.06 (s, 3H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃, rotamers) δ 211.8, 155.8, 79.2, 37.0, 34.2, 28.6 (28.5), 25.8 (25.6), 18.1, -4.9, -5.0 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₆H₃₃NO₄SiNa⁺ 354.2071, found 354.2080.

(*S*)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-oxohexylcarbamate (**8**f). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). Colorless oil (380 mg, 55%). [α]_D²⁷ -18.1 (*c* 1.00, CHCl₃); IR (film) ν_{max} 3368, 2935, 2858, 1715, 1513, 1256, 1164, 841, 775 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.79 (s, 1H), 4.21–4.07 (m, 1H), 3.27–3.07 (m, 2H), 2.65–2.47 (m, 2H), 1.93–1.77 (m, 2H), 1.43 (s, 9H), 1.09– 0.98 (m, 3H), 0.96–0.91 (m, 9H), 0.11–0.01 (m, 6H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 214.2, 155.9, 79.2, 77.3, 37.1, 34.6, 31.1, 28.5, 25.9, 18.2, 7.4, -4.9 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₇H₃₅NO₄SiNa⁺ 368.2228, found 368.2226.

(S)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-oxooctylcarbamate (**8g**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). Colorless oil (635 mg, 85%). [α]_D²⁴ -13.4 (*c* 1.00, CHCl₃); IR (film) ν_{max} 2960, 2854, 1711, 1590, 1260, 1175, 841, 775 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.82 (s, 1H), 4.17–4.07 (m, 1H), 3.25–3.12 (m, 2H), 2.56–2.49 (m, 2H), 1.92–1.78 (m, 2H), 1.56–1.51 (m, 2H), 1.43 (s, 9H), 1.36–1.27 (m, 4H), 0.93 (s, 9H), 0.91–0.88 (m, 3H), 0.09–0.05 (m, 6H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 213.6, 155.9, 79.2, 71.7, 37.5, 37.1, 34.3, 28.5 (28.1), 25.8, 25.3, 22.5, 18.1, 14.0, -4.9, -5.0 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₉H₃₉NO₄SiNa⁺ 396.2541, found 396.2538.

(5)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-oxononylcarbamate (**8h**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). Colorless oil (628 mg, 81%). [α]_D²⁵ -10.2 (*c* 1.00, CHCl₃); IR (film) ν_{max} 2931, 1715, 1594, 1256, 1175, 1120, 837, 778 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.82 (*s*, 1H), 4.17–4.07 (m, 1H), 3.27–3.14 (m, 2H), 2.59–2.48 (m, 2H), 1.92–1.78 (m, 2H), 1.60–1.51 (m, 2H), 1.43 (*s*, 9H), 1.35–1.24 (m, 4H), 0.94 (*s*, 9H), 0.92–0.88 (m, 3H), 0.10–0.04 (m, 6H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 213.6, 155.9, 79.2, 37.8, 37.2, 34.4, 31.6, 28.5, 25.9, 23.0, 22.6, 18.2, 14.0, -4.8, -5.0 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₂₀H₄₁NO₄SiNa⁺ 410.2697, found 410.2696. (*S*)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-5-methyl-4-oxohexylcarbamate (**8***i*). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). White solid (503 mg, 70%). [α]_D²⁵ +13.2 (*c* 1.00, CHCl₃); mp 53–54 °C; IR (film) ν_{max} 2971, 1711, 1590, 1249, 1175, 837, 775 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 4.84 (s, 1H), 4.30–4.21 (m, 1H), 3.26–3.11 (m, 2H), 3.08–2.95 (m, 1H), 1.94–1.84 (m, 2H), 1.42 (s, 9H), 1.11–1.02 (m, 6H), 0.96–0.91 (m, 9H), 0.10–0.03 (m, 6H) ppm; ¹³C{¹H} NMR (400 MHz, CDCl₃) δ 216.5, 155.9, 79.2, 76.5, 37.3, 35.4, 34.3, 28.5, 25.8, 19.3, 18.3, -4.8, -4.9 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₈H₃₇NO₄SiNa⁺ 382.2384, found 382.2380.

(S)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-oxo-4-phenylbutylcarbamate (**8***j*). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). Colorless oil (614 mg, 78%). [α]_D²⁵ -27.9 (*c* 1.00, CHCl₃); IR (film) ν_{max} 2927, 2858, 1697, 1590, 1252, 1168, 833, 778 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 8.16-8.08 (m, 2H), 7.73-7.65 (m, 1H), 7.61-7.49 (m, 2H), 5.17-4.96 (m, 2H), 3.50-3.25 (m, 2H), 2.21-2.06 (m, 2H), 1.54 (s, 9H), 1.08-0.97 (m, 9H), 0.19-0.12 (m, 6H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃, rotamers) δ 201.0, 155.9, 134.8, 133.4, 129.0 (128.7), 128.0 (127.3), 79.2, 75.9, 37.6, 35.2, 28.4, 25.9, 18.3, -4.6, -5.2 ppm; HRMS (ESI-Orbitrap) *m*/*z* [M + Na]⁺ calcd for C₂₁H₃₅NO₄SiNa⁺ 416.2228, found 416.2228.

(*S*)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-oxo-4-m-tolylbutylcarbamate (**8**k). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). Light yellow semisolid (701 mg, 86%). [α]_D²⁷ -43.1 (*c* 1.00, CHCl₃); IR (film) ν_{max} 3383, 2927, 1697, 1513, 1249, 1171, 833, 775 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.86–7.76 (m, 2H), 7.44–7.30 (m, 2H), 5.05–4.87 (m, 2H), 3.37–3.21 (m, 2H), 2.42 (s, 3H), 2.10–1.91 (m, 2H), 1.43 (s, 9H), 0.93 (s, 9H), 0.08 (s, 3H), 0.02 (s, 3H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 201.1, 156.0, 138.5, 134.9, 134.2, 129.5, 128.5, 126.2, 79.2, 75.9, 37.8, 35.3, 28.5, 25.9, 21.5, 18.3, -4.5, -5.2 ppm; HRMS (ESI-Orbitrap) *m*/*z* [M + Na]⁺ calcd forC₂₂H₃₇NO₄SiNa⁺ 430.2384, found 430.2390.

(5)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-oxo-4-p-tolylbutylcarbamate (8)). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). Colorless oil (759 mg, 93%). [α]_D²⁶ -43.2 (*c* 1.00, CHCl₃); IR (film) ν_{max} 3383, 2927, 2854, 1715.07, 1252, 1146, 837, 771 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.98–7.83 (m, 2H), 7.28–7.25 (m, 2H), 5.02– 4.85 (m, 2H), 3.36–3.25 (m, 2H), 2.43 (s, 3H), 2.08–1.93 (m, 2H), 1.44 (s, 9H), 0.92 (s, 9H), 0.07 (s, 3H), 0.02 (s, 3H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 200.5, 155.9, 144.3, 132.2, 129.4, 129.2, 79.2, 75.9, 37.8, 35.4, 28.5, 25.9, 21.8, 18.4, -4.5, -5.2 ppm; HRMS (ESI-Orbitrap) *m*/*z* [M + Na]⁺ calcd for C₂₂H₃₇NO₄SiNa⁺ 430.2384, found 430.2379.

(S)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-(3-chlorophenyl)-4-oxobutylcarbamate (**8m**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). White semisolid (651 mg, 76%). $[\alpha]_D^{25}$ +12.7 (c 1.00, CHCl₃); IR (film) ν_{max} 3445, 2935, 1693, 1384, 1124, 837, 778 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 7.44–7.38 (m, 1H), 7.31–7.22 (m, 3H), 4.26–3.92 (m, 2H), 3.82–3.74 (m, 1H), 3.65–3.49 (m, 1H), 2.17–1.93 (m, 2H), 1.55–1.29 (m, 4H), 1.15–1.09 (m, 5H), 0.91– 0.84 (m, 9H), -0.08 (s, 3H), -0.19 (s, 3H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃, rotamers) δ 199.9, 154.2, 147.3, 134.1 (133.3), 129.4, 127.3, 126.0, 123.7, 88.7 (83.2), 80.4 (81.2), 71.8, 44.0 (41.9), 30.0, 28.1 (28.5), 25.7 (25.9), 18.1, -5.0,-5.2 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₂₁H₃₄ClNO₄SiNa⁺ 450.1838, found 450.1834.

(5)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-(4-chlorophenyl)-4-oxobutylcarbamate (**8***n*). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). Colorless oil (719 mg, 84%). [α]_D²⁷ -28.8 (*c* 1.00, CHCl₃); IR (film) ν_{max} 2927, 2861, 1704, 1587, 1252, 1175, 841, 778 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.04-7.89 (m, 2H), 7.46-7.41 (m, 2H), 4.93-4.74 (m, 2H), 3.39-3.23 (m, 2H), 2.07-1.96 (m, 2H), 1.43 (s, 9H), 0.91 (s, 9H), 0.08 (s, 3H), 0.01 (s, 3H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃, rotamers) δ 199.9, 155.9, 139.9, 132.9, 130.8, 129.0 (128.6), 79.3, 76.4, 37.7, 35.5, 28.5, 25.9 (25.7), 18.3, -4.6, -5.2 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₂₁H₃₄ClNO₄SiNa⁺ 450.1838, found 450.1839.

(S)-tert-Butyl 3-(tert-butyl/dimethylsilyloxy)-4-(4-methoxyphenyl)-4-oxobutylcarbamate (**80**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). Colorless oil (466 mg, 55%). [α]_D²⁴ -22.1 (*c* 2.00, CHCl₃); IR (film) ν_{max} 3361, 2927, 2865, 1697, 1598, 1509, 1260, 1175, 833, 775 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.10–7.99 (m, 2H), 6.97–6.90 (m, 2H), 4.98–4.81 (m, 2H), 3.89 (s, 3H), 3.37–3.24 (m, 2H), 2.10–1.92 (m, 2H), 1.44 (s, 9H), 0.92 (s, 9H), 0.07 (s, 3H), 0.01 (s, 3H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 199.4, 163.7, 155.9, 131.6, 127.6, 113.9, 79.2, 76.2, 55.6, 37.8, 35.6, 28.5, 25.9, 18.3, -4.6, -5.2 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₂₂H₃₇NO₅SiNa⁺ 446.2333, found 446.2332.

(*S*)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-oxo-5-phenylpentylcarbamate (**8***p*). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). Light yellow oil (653 mg, 80%). [α]_D²⁶ +2.6 (*c* 0.50, CHCl₃); IR (film) ν_{max} 2927, 1708, 1583, 1249, 1160, 833, 786 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.34–7.17 (m, 5H), 4.75 (s, 1H), 4.28–4.17 (m, 1H), 3.95–3.76 (m, 2H), 3.26–3.08 (m, 2H), 2.02–1.76 (m, 2H), 1.43 (s, 9H), 0.95 (s, 9H), 0.06 (s, 6H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 210.5, 155.9, 133.8, 129.8, 128.7, 127.1, 79.3, 44.6, 37.1, 34.5, 28.5, 25.9, 18.2, -4.8, -5.0 ppm; HRMS (ESI-Orbitrap) *m*/*z* [M + Na]⁺ calcd for C₂₂H₃₇NO₄SiNa⁺ 430.2384, found 430.2380.

(*S*)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-oxo-5-m-tolylpentylcarbamate (**8q**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). Colorless oil (371 mg, 44%). $[\alpha]_D^{25}$ -2.6 (*c* 1.00, CHCl₃); IR (film) ν_{max} 3376, 2931, 1715, 1256, 1171, 841, 778 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.29–7.21 (m, 1H), 7.12–7.07 (m, 1H), 7.03–6.97 (m, 2H), 4.80 (s, 1H), 4.32–4.23 (m, 1H), 3.93–3.76 (m, 2H), 3.28–3.14 (m, 2H), 2.36–2.32 (m, 3H), 2.03–1.79 (m, 2H), 1.46 (s, 9H), 0.98 (s, 9H), 0.09 (s, 6H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 210.5, 155.9, 138.3, 133.7, 130.6, 128.6, 127.9, 126.8, 79.3, 77.5, 44.6, 37.1, 34.5, 28.5, 25.9, 21.5, 18.2, -4.8, -5.0 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₂₃H₃₉NO₄SiNa⁺ 444.2541, found 444.2540.

(S)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-4-oxohept-6-enylcarbamate (8r). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 8:1, R_f = 0.3). White solid (315 mg, 44%). [α]_D²³ -7.4 (*c* 1.00, CHCl₃); IR (film) ν_{max} 3361, 2931, 1711, 1509, 1252, 1164, 837, 778 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 5.99–5.86 (m, 1H), 5.22–5.11 (m, 2H), 4.79 (s, 1H), 4.20–4.14 (m, 1H), 3.41–3.31 (m, 2H), 3.24– 3.19 (m, 2H), 1.95–1.83 (m, 2H), 1.43 (s, 9H), 0.96–0.93 (m, 9H), 0.09 (s, 3H), 0.07 (s, 3H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 211.3, 155.8, 130.4, 118.9, 79.3, 77.8, 42.5, 37.0, 34.4, 28.5, 25.9, 18.2, -4.9, -5.0 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₈H₃₅NO₄SiNa⁺ 380.2228, found 380.2231.

(25,35)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-2-(dimethoxyphosphoryl)-2-ethynylpyrrolidine-1-carboxylate (9a). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, R_f = 0.3). Yellow solid (178 mg, 82%). [α]_D²⁵ +15.2 (*c* 0.50, CHCl₃); mp 93–95 °C; IR (film) ν_{max} 2927, 1590, 1388, 1124, 1043, 837, 775 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.54 (ddd, *J* = 17.6, 7.6, 6.8 Hz, 1H), 3.88–3.80 (m, 6H), 3.63– 3.51 (m, 2H), 2.68–2.54 (m, 1H), 2.33–2.22 (m, 1H), 2.12–2.01 (m, 1H), 1.48 (s, 9H), 0.93 (s, 9H), 0.16 (s, 3H), 0.13 (s, 3H) ppm; ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆, Temp = 75 °C) δ 152.2, 81.9 (d, *J* = 4.6 Hz), 80.1 (d, *J* = 2.6 Hz), 79.2, 77.0 (d, *J* = 8.9 Hz), 61.2 (d, *J* = 168.8 Hz), 53.1 (d, *J* = 7.2 Hz), 52.8 (d, *J* = 7.4 Hz), 44.5, 29.8, 27.7, 25.3, 17.4, -5.0, -5.3 ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 18.2 ppm; HRMS (ESI-Orbitrap) *m*/*z* [M + Na]⁺ calcd for C₁₉H₃₆NO₆PSiNa⁺ 456.1942, found 456.1941.

(25,35)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-2-(dimethoxyphosphoryl)-2-(2-phenylethynyl)pyrrolidine-1-carboxylate (9b). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, $R_f = 0.3$). Yellow oil (186 mg, 73%). $[\alpha]_D^{25}$ +13.8 (*c* 1.00, CHCl₃); IR (film) ν_{max} 2920, 1594, 1381, 1252, 1124, 1032, 837, 756 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.45–7.42 (m, 2H), 7.34–7.29 (m, 3H), 4.62 (ddd, *J* = 16.8, 7.2, 6.4 Hz, 1H), 3.89–3.82 (m, 6H), 3.64–3.58 (m, 2H), 2.39–2.23 (m, 1H), 2.14–2.03 (m, 1H), 1.49 (s, 9H), 0.93 (m, 9H), 0.17 (s, 3H), 0.14 (s, 3H) ppm; ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆, Temp = 75 °C) δ 152.3, 130.7 (d, *J* = 2.2 Hz), 128.3, 122.1 (d, *J* = 2.6 Hz), 86.4 (d, *J* = 167.4 Hz), 53.2 (d, *J* = 7.3 Hz), 53.0 (d, *J* = 7.5 Hz), 44.4, 29.7, 27.7, 25.3, 17.4, –5.1, –5.3 ppm; ³¹P NMR (162 MHz, CDCl₃) δ 18.2 ppm; HRMS (ESI-Orbitrap) *m*/*z* [M + Na]⁺ calcd for C₂₅H₄₀NO₆PSiNa⁺ 532.2255, found 532.2259.

(25,35)-tert-Butyl 3-((tert-butyldimethylsilyl)oxy)-2-(dimethoxyphosphoryl)-2-(p-tolylethynyl)pyrrolidine-1-carboxylate (9c). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, R_f = 0.3). Colorless oil (209 mg, 80%). [α]_D²³ +29.3 (c 3.00, CHCl₃); IR (film) ν_{max} 3372, 2971, 1715, 1520, 1370, 1252, 1175, 1047 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.34– 7.29 (m, 2H), 7.14–7.05 (m, 2H), 4.60 (ddd, *J* = 18.0, 7.2, 6.4 Hz, 1H), 3.88–3.79 (m, 6H), 3.66–3.54 (m, 2H), 2.33 (s, 3H), 2.14– 2.04 (m, 1H), 1.48 (s, 9H), 0.92 (s, 9H), 0.16 (s, 3H), 0.13 (s, 3H) pm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 153.7, 138.5, 131.5, 129.1, 119.7, 87.0 (d, *J* = 8.6 Hz), 85.2, 82.6, 80.2, 62.7 (d, *J* = 170.4 Hz), 54.1 (d, *J* = 7.5 Hz), 53.9, 45.3, 30.8, 28.4, 25.7, 21.5, 18.2, -4.5, -4.8 pm; ³¹P NMR (162 MHz, CDCl₃) δ 18.3 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₂₆H₄₂NO₆PSiNa⁺ 546.2411, found 546.2409.

(25,35)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-2-(2-(4-chlorophenyl)ethynyl)-2-(dimethoxyphosphoryl)pyrrolidine-1-carboxylate (9d). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, R_f = 0.3). Colorless oil (212 mg, 78%). [α]_D²⁴ +34.3 (c 2.00, CHCl₃); IR (film) ν_{max} 2957, 2854, 1689, 1388, 1256, 1124, 1043, 830, 547 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.40–7.34 (m, 2H), 7.31–7.26 (m, 2H), 4.60 (ddd, J = 18.8, 7.2, 6.4 Hz, 1H), 3.89–3.79 (m, 6H), 3.66–3.53 (m, 2H), 2.41–2.29 (m, 1H), 2.15–2.05 (m, 1H), 1.49 (s, 9H), 0.93 (s, 9H), 0.17 (s, 3H), 0.14 (s, 3H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 153.6, 134.5, 132.9, 128.7, 121.4, 87.1, 85.8 (d, J = 8.3 Hz), 82.6, 80.4, 63.4, 62.5 (d, J = 170.4 Hz), 54.0 (d, J = 7.3 Hz), 45.3, 30.9, 28.5, 25.8, 18.3, -4.5, -4.7 ppm; ³¹P NMR (162 MHz, CDCl₃) δ 18.2 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₂₅H₃₀ClNO₆PSiNa⁺566.1865, found 566.1869.

(25,35)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-2-(dimethoxyphosphoryl)-2-methylpyrrolidine-1-carboxylate (**9e**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, R_f = 0.3). Light yellow solid (165 mg, 78%). [α]_D²⁷ +49.3 (*c* 1.00, CHCl₃); mp 68–69 °C; IR (film) ν_{max} 2949, 1711, 1366, 1252, 1157, 1039, 837, 771 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.00–3.86 (m, 1H), 3.81–3.69 (m, 6H), 3.59–3.51 (m, 1H), 3.50–3.37 (m, 1H), 2.40–2.25(m, 1H), 1.99–1.93 (m, 1H), 1.76–1.60 (m, 3H), 1.46 (s, 9H), 0.93 (s, 9H), 0.12 (s, 3H), 0.10 (s, 3H) ppm; ¹³C{¹H} NMR (100 MHz, DMSO- d_6 , Temp = 75 °C) δ 152.6, 81.5, 78.5, 64.2 (d, *J* = 160.0 Hz), 52.0 (d, *J* = 7.0 Hz), 51.4 (d, *J* = 7.5 Hz), 44.4, 28.5, 27.8, 25.2, 20.7 (d, *J* = 5.8 Hz), 17.3, -5.0, -5.3 ppm; ³¹P NMR (162 MHz, CDCl₃) δ 25.8 ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₈H₃₈NO₆PSiNa⁺ 446.2098, found 446.2097.

(25,35)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-2-(dimethoxyphosphoryl)-2-ethylpyrrolidine-1-carboxylate (9f). The title compound was purified by column chromatography (petroleum ether/ ethyl acetate = 2:1, R_f = 0.3). Colorless oil (153 mg, 70%). $[\alpha]_D^{26}$ +18.2 (c 1.00, CHCl₃); IR (film) ν_{max} 2957, 1711, 1373, 1252, 1149, 1032, 833, 778 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 4.30– 4.14 (m, 1H), 3.80–3.70 (m, 6H), 3.63–3.55 (m, 1H), 3.42–3.28 (m, 1H), 2.68–2.35(m, 2H), 2.01–1.88 (m, 2H), 1.05–1.44 (m, 9H), 0.94 (s, 9H), 0.87–0.79 (m, 3H), 0.16–0.06 (m, 6H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃, rotamers) δ 154.5 (153.1), 80.2 (79.3), 74.7 (74.2), 69.2 (d, J = 154.7 Hz), 53.1 (d, J = 6.6 Hz), 52.3 (d, J = 7.0 Hz), 45.7 (45.3), 29.5, 28.5 (28.7), 25.8, 22.7 (d, J = 5.6 Hz), 18.2, 6.8 (7.0, 6.7), -4.4, -4.8 ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 26.8 (25.9) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₁₉H₄₀NO₆PSiNa⁺ 460.2255, found 460.2258.

(2S,3S)-tert-Butyl 2-butyl-3-(tert-butyldimethylsilyloxy)-2-(dimethoxyphosphoryl)pyrrolidine-1-carboxylate (9g). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, $R_f = 0.3$). Colorless oil (140 mg, 60%). $[\alpha]_{D}^{25}$ +15.4 (c 2.00, CHCl₃); IR (film) ν_{max} 2953, 1711, 1377, 1249, 1149, 1028, 841, 771 cm⁻¹; ¹H NMR (400 MHz, CDCl₂, rotamers) δ 4.33-4.16 (m, 1H), 3.79-3.66 (m, 6H), 3.64-3.55 (m, 1H), 3.40-3.25 (m, 1H), 2.59-2.27(m, 2H), 1.79-1.83 (m, 2H), 1.51-1.43 (m, 9H), 1.41-1.29 (m, 2H), 1.22-1.07 (m, 2H), 0.93 (s, 9H), 0.93-0.86 (m, 3H), 0.14–0.07 (m, 6H) ppm; $^{13}\mathrm{C}\{^{1}\mathrm{H}\}$ NMR (100 MHz, $CDCl_3$, rotamers) δ 154.5 (153.0), 80.2 (79.3), 75.5 (75.0), 68.3 (d, J = 164.4 Hz), 53.2 (d, J = 6.7 Hz) (53.0), 52.3 (d, J = 7.1 Hz) (52.2), 45.7 (45.3), 30.1 (d, J = 5.2 Hz), 29.5 (d, J = 4.9 Hz), 28.4 (28.8), 25.7, 24.9 (d, J = 10.8 Hz) (24.6), 22.9 (d, J = 18.1 Hz), 18.1, 14.5, -4.4, -4.8 ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 26.7 (25.8) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C21H44NO6PSiNa+ 488.2568, found 488.2569.

(2S,3S)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-2-(dimethoxyphosphoryl)-2-pentylpyrrolidine-1-carboxylate (9h). The title compound was purified by column chromatography (petroleum ether/ ethyl acetate = 2:1, R_f = 0.3). White solid (134 mg, 56%). $[\alpha]_D^{25}$ +17.4 (c 1.00, CHCl₃); mp 69–70 °C; IR (film) ν_{max} 2953, 1711, 1594, 1373, 1252, 1039, 775 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 4.35-4.15 (m, 1H), 3.75-3.68 (m, 6H), 3.61-3.53 (m, 1H), 3.39-3.23 (m, 1H), 2.58-2.29 (m, 2H), 1.95-1.80 (m, 2H), 1.49-1.43 (m, 9H), 1.36-1.26 (m, 4H), 1.23-1.09 (m, 2H), 0.92 (s, 9H), 0.91–0.85 (m, 3H), 0.11–0.07 (m, 6H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₂, rotamers) δ 154.5 (153.0), 80.1 (79.2), 75.5 (74.9), 68.3 (d, J = 154.5 Hz), 53.1 (d, J = 6.6 Hz) (53.0), 52.3 (d, J = 7.1 Hz) (52.1), 45.7 (45.3), 32.1 (31.9), 30.3 (d, J = 5.2 Hz), 29.5, 28.4 (28.8), 25.8, 22.9 (d, J = 15.7 Hz), 22.1 (d, J = 10.1 Hz), 18.1, 14.1 (d, J = 13.6 Hz), -4.4, -4.8 ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 26.7 (25.8) ppm; HRMS (ESI-Orbitrap) m/z [M + Na] calcd for C₂₂H₄₆NO₆PSiNa⁺ 502.2724, found 502.2726.

(2S,3S)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-2-(dimethoxyphosphoryl)-2-isopropylpyrrolidine-1-carboxylate (9i). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, $R_f = 0.3$). Colorless oil (93 mg, 41%). $[\alpha]_{\rm D}^{25}$ +14.9 (c 1.00, CHCl_3); IR (film) $\nu_{\rm max}$ 2949, 1711, 1366, 1244.90, 1036, 833, 775, 551 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) & 4.47-4.29 (m, 1H), 3.82-3.65 (m, 6H), 3.64-3.55 (m, 1H), 3.43-3.26 (m, 1H), 3.19-2.98 (m, 1H), 2.28-2.02 (m, 1H), 1.99-1.88 (m, 1H), 1.54-1.39 (m, 9H), 1.26-1.16 (m, 3H), 0.92 (s, 9H), 0.84 (d, J = 6.8 Hz, 3H), 0.16–0.08 (m, 6H) ppm; ${}^{13}C{}^{1}H$ NMR (100 MHz, CDCl₃, rotamers) δ 154.7 (153.3), 80.5 (79.3), 74.7 (73.9), 73.2 (d, J = 152.3 Hz), 52.5 (d, J = 7.1 Hz), 46.4 (d, J = 13.7 Hz), 31.5 (31.4), 29.7 (d, J = 7.8 Hz), 29.3 (d, J = 8.2 Hz), 28.5, 25.9, 18.9 (19.2), 18.1 (17.9), -3.6, -4.8 ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 27.3 (26.8) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for $C_{20}H_{42}NO_6PSiNa^+$ 474.2411, found 474.2411.

(2R,3S)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-2-(dimethoxyphosphoryl)-2-isopropylpyrrolidine-1-carboxylate (9i-2). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, $R_f = 0.3$). Colorless oil (32 mg, 14%). $[\alpha]_{\rm D}^{24}$ +2.6 (c 2.00, CHCl₃); IR (film) $\nu_{\rm max}$ 2954, 1701, 1385, 1249.06, 1022, 831, 770, 560 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) & 4.95-4.84 (m, 1H), 3.82-3.70 (m, 6H), 3.66-3.47 (m, 2H), 3.08-2.95 (m, 1H), 2.09-1.96 (m, 1H), 1.79-1.66 (m, 1H), 1.51-1.46 (m, 9H), 1.28 (d, J = 7.2 Hz, 3H), 1.06 (d, J = 6.8 Hz, 3H), 0.91 (s, 9H), 0.16–0.08 (m, 6H) ppm; $^{13}\mathrm{C}\{^{1}\mathrm{H}\}$ NMR (100 MHz, CDCl₃, rotamers) δ 154.9 (154.5), 80.5 (79.6), 77.7 (d, J = 7.9 Hz) (78.7), 73.1 (d, J = 138.4 Hz) (73.7), 53.7 (d, J = 7.0 Hz), 52.1 (d, J = 7.2 Hz), 46.8 (46.3), 33.1 (32.2), 29.7 (d, J = 5.8 Hz) (30.1), 28.6 (28.5), 26.1, 18.9 (d, J = 12.6 Hz) (18.5), 18.1 (17.9), -4.2, -4.4 ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 33.7 (31.1) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for $C_{20}H_{42}NO_6PSiNa^+$ 474.2411, found 474.2408.

(2S,3S)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-2-(dimethoxyphosphoryl)-2-phenylpyrrolidine-1-carboxylate (9i). The title compound was purified by column chromatography (petroleum ether/ ethyl acetate = 2:1, R_f = 0.3). Pink solid (146 mg, 60%). $[\alpha]_D^{25}$ +10.3 (c 1.00, CHCl₃); mp 116–117 °C; IR (film) $\tilde{\nu_{max}}$ 2953, 2854, 1689, 1388, 1245, 1108.98, 1054, 837 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 7.52-7.26 (m, 5H), 4.66-4.56 (m, 1H), 3.91-3.61 (m, 5H), 3.59-3.40 (m, 3H), 1.74-1.66 (m, 2H), 1.59-1.50 (m, 5H), 1.47-1.32 (m, 4H), 1.00-0.88 (m, 9H), 0.21-0.02 (m, 6H) ppm; $^{13}C{^{1}H}$ NMR (100 MHz, CDCl₃, rotamers) δ 154.9 (154.3), 138.7 (138.3), 128.5 (128.2), 127.4, 126.6 (126.3), 85.0 (82.8), 80.5 (79.8), 75.5 (d, J = 162.9 Hz), 53.4 (d, J = 4.7 Hz) (53.9), 51.9 (d, J = 5.2Hz), 47.4 (47.0), 30.7 (d, J = 7.6 Hz) (29.9), 28.6 (28.4), 26.9, 18.2, -4.7, -5.0 ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 23.2 (22.8) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₂₃H₄₀NO₆PSiNa⁺ 508.2255, found 508.2257.

(2R,3S)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-2-(dimethoxyphosphoryl)-2-phenylpyrrolidine-1-carboxylate (9j-2). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, $R_f = 0.3$). Colorless oil (63 mg, 26%). $[\alpha]_{D}^{24}$ +29.5 (*c* 2.00, CHCl₃); IR (film) ν_{max} 2953, 2850, 1700, 1384, 1249, 1054, 1024, 830 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 7.34-7.17 (m, 5H), 4.91-4.78 (m, 1H), 3.85-3.68 (m, 8H), 2.28-2.16 (m, 1H), 1.81-1.68 (m, 1H), 1.51-1.45 (m, 5H), 1.22-1.19 (m, 4H), 0.64–0.58 (m, 9H), -0.10 (s, 3H), -0.31 to -0.42 (m, 3H) ppm; ${}^{13}C{}^{1}H$ NMR (100 MHz, CDCl₃, rotamers) δ 154.7 (154.4), 135.6 (d, J = 6.5 Hz) (136.5), 127.6 (d, J = 5.2 Hz) (127.8), 127.2 (126.9), 126.8 (126.6), 80.5 (80.0), 77.8 (d, J = 5.7 Hz) (79.2), 74.7 (d, J = 151.0 Hz) (75.2), 54.2 (d, J = 7.2 Hz) (54.4), 52.6 (d, J = 8.0 Hz)Hz) (52.4), 46.4 (46.6), 32.4 (32.0), 28.6 (28.0), 25.5 (25.4), 17.7 (d, J = 5.9 Hz), -4.8 (-5.0), -5.4 (-5.5) ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 29.5 (27.4) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for $C_{23}H_{40}NO_6PSiNa^+$ 508.2255, found 508.2258.

(2S,3S)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-2-(dimethoxyphosphoryl)-2-m-tolylpyrrolidine-1-carboxylate (9k). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, $R_f = 0.3$). Yellow solid (140 mg, 56%). $[\alpha]_{\rm D}^{27}$ +9.4 (c 1.00, CHCl₃); mp 137–138 °C; IR (film) $\nu_{\rm max}$ 2953, 1693, 1392, 1245, 1113, 1061, 834, 775 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 7.36–7.15 (m, 3H), 7.10–7.02 (m, 1H), 4.64– 4.52 (m, 1H), 3.87-3.58 (m, 5H), 3.56-3.33 (m, 3H), 2.34(s, 3H), 1.78-1.51 (m, 2H), 1.57-1.31 (m, 9H), 1.00-0.85 (m, 9H), 0.22-0.01 (m, 6H) ppm; ${}^{13}C{}^{1}H$ NMR (100 MHz, CDCl₃, rotamers) δ 154.2 (155.0), 138.1 (138.4), 137.8 (137.7), 128.3, 128.1 (128.0), 127.0 (127.1), 123.5 (123.7), 82.8 (84.8), 79.7 (80.5), 75.4 (d, J = 162.8 Hz) (75.2), 53.5 (d, J = 6.3 Hz) (53.2, 53.9), 51.8 (d, J = 6.9Hz), 47.0 (d, J = 3.3 Hz) (47.4), 30.7 (d, J = 7.4 Hz) (29.8), 28.6 (28.4), 26.0, 21.9 (21.7), 18.2, -4.5, -4.9 ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 23.2 (22.7) ppm; HRMS (ESI-Orbitrap) m/z [M + H]⁺ calcd for $C_{24}H_{43}NO_6PSi^+$ 500.2592, found 500.2595.

(2R,3S)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-2-(dimethoxyphosphoryl)-2-m-tolylpyrrolidine-1-carboxylate (9k-2). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, $R_f = 0.3$). Pink oil (75 mg, 30%). $[\alpha]_{D}^{23}$ +41.3 (c 3.00, CHCl₃); IR (film) $\nu_{\rm max}$ 2953, 1697, 1396, 1252, 1058, 1028, 833, 778 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 7.18– 6.93 (m, 4H), 4.92-4.72 (m, 1H), 3.83-3.65 (m, 8H), 2.30 (d, J = 4.4 Hz, 3H), 2.23-2.13 (m, 1H), 1.79-1.65 (m, 1H), 1.50-1.20 (m, 9H), 0.64–0.59 (m, 9H), -0.10 (m, 3H), -0.31 to -0.45 (m, 3H) ppm; ${}^{13}C{}^{1}H$ NMR (100 MHz, CDCl₃, rotamers) δ 154.7 (154.3), 136.2 (136.0), 135.3 (135.2), 128.4 (d, J = 5.5 Hz, 128.6), 127.5 (127.1), 127.2 (126.8), 124.5, 124.5 (124.6), 80.3 (79.9), 77.8 (d, J = 6.3 Hz) (79.2), 74.6 (d, J = 150.5 Hz) (75.3), 54.1 (d, J = 7.2 Hz) (54.4), 52.7 (d, J = 8.0 Hz) (52.3), 46.6 (46.3), 32.1 (d, J = 2.7 Hz) (32.5), 28.5 (28.0), 25.5 (d, J = 5.3 Hz), 21.7 (21.5), 17.7 (17.6), -4.9 (-5.0), -5.5 (-5.6) ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 29.5 (27.3) ppm; HRMS (ESI-Orbitrap) m/z [M + Na] calcd for C₂₄H₄₂NO₆PSiNa⁺ 522.2411, found 522.2415.

(25,35)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-2-(dimethoxy-phosphoryl)-2-p-tolylpyrrolidine-1-carboxylate (91). The title com-

pound was purified by column chromatography (petroleum ether/ ethyl acetate = 2:1, $R_f = 0.3$). Colorless oil (132 mg, 53%). $[\alpha]_D^{25}$ +10.9 (c 2.00, CHCl₃); IR (film) ν_{max} 2953, 2854, 1686, 1392, 1252, 1061, 841, 778 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 7.38– 7.10 (m, 4H), 4.64–4.54 (m, 1H), 3.87–3.60 (m, 5H), 3.58–3.36 (m, 3H), 2.33 (s, 3H), 1.75–1.58 (m, 2H), 1.56–1.34 (m, 9H), 0.98–0.90 (m, 9H), 0.19 (s, 3H), 0.13–0.05 (m, 3H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃, rotamers) δ 154.2 (155.0), 137.0, 135.3, 129.1 (128.8), 126.2 (126.4), 82.7 (84.8), 79.7 (80.5), 75.3 (d, J = 163.3 Hz) (75.1), 53.2 (d, J = 6.6 Hz) (53.4, 53.9), 51.8, 47.0 (47.4), 30.7 (d, J = 6.8 Hz) (29.7), 28.6 (28.4), 26.0, 21.0, 18.2, -4.5, -4.9 ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 23.4 (22.8) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₂₄H₄₂NO₆PSiNa⁺ 522.2411, found 522.2418.

(2R.3S)-tert-Butyl 3-(tert-butyldimethylsilvloxy)-2-(dimethoxyphosphoryl)-2-p-tolylpyrrolidine-1-carboxylate (91-2). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, $R_f = 0.3$). Colorless oil (65 mg, 26%). $[\alpha]_{\rm D}^{23}$ +22.7 (c 3.00, CHCl₃); IR (film) $\nu_{\rm max}$ 2953, 2850, 1689, 1384, 1245, 1054, 833, 775, 558 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) & 7.23-7.12 (m, 2H), 7.08-7.03 (m, 2H), 4.90-4.75 (m, 1H), 3.85-3.68 (m, 8H), 2.30 (d, J = 10.8 Hz, 3H), 2.24-2.14 (m, 1H), 1.78-1.63 (m, 1H), 1.51-1.22 (m, 9H), 0.66-0.69 (m, 9H), -0.09 (s, 3H), -0.27 to -0.43(m, 3H) ppm; $^{13}C{^{1}H}$ NMR (100 MHz, CDCl₂, rotamers) δ 154.4 (154.7), 136.1 (d, I = 7.4 Hz), 132.3 (d, I = 6.5 Hz) (133.2), 127.9, 127.5, 79.9 (80.4), 77.7 (d, I = 6.0 Hz)(79.1), 74.4 (d, J = 151.0 Hz) (75.0), 54.2 (d, J = 7.2 Hz) (54.4), 52.4, 52.5 (52.2), 46.3 (46.5), 32.5 (d, J = 3.3 Hz) (32.1), 28.6 (28.1), 25.5 (d, J = 5.8 Hz), 21.0, 17.8 (17.7), -4.8 (-4.9), -5.4 (-5.5) ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 29.7 (27.5) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₂₄H₄₂NO₆PSiNa⁺ 522.2411, found 522.2419.

(2S,3S)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-2-(3-chlorophenyl)-2-(dimethoxyphosphoryl)pyrrolidine-1-carboxylate (**9m**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, $R_f = 0.3$). White solid (182 mg, 70%). $[\alpha]_{D}^{25}$ +5.8 (c 2.00, CHCl₃); mp 156–156 °C; IR (film) ν_{max} 2953, 1708, 1396, 1249, 1058, 833, 775, 580 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) & 7.51-7.19 (m, 4H), 4.60-4.48 (m, 1H), 3.89-3.43 (m, 8H), 1.86-1.59 (m, 2H), 1.58-1.26 (m, 9H), 1.01-0.85 (m, 9H), 0.21-0.02 (m, 6H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃, rotamers) δ 154.1 (154.6), 141.1 (140.7), 134.3, 129.6 (129.4), 127.6, 126.7 (126.9), 124.6 (124.9), 82.9 (85.1), 80.1 (80.8), 74.9 (d, J = 163.4 Hz) (74.4), 53.3 (d, J = 6.3 Hz) (53.5, 53.9), 52.1 (d, J = 6.5 Hz), 46.8 (47.1), 30.7 (29.9), 28.6 (28.3), 25.9, 18.2, -4.6, -4.9 ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 22.8 (22.4) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₂₃H₃₉ClNO₆PSiNa⁺ 542.1865, found 542.1866.

(2R,3S)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-2-(3-chlorophenyl)-2-(dimethoxyphosphoryl)pyrrolidine-1-carboxylate (9m-2). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, $R_f = 0.3$). Colorless oil (26 mg, 10%). $[\alpha]_{\rm D}^{25}$ +24.4 (c 1.00, CHCl₃); IR (film) $\nu_{\rm max}$ 2953, 1700, 1377, 1249, 1050, 1028, 830, 775 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 7.29-7.16 (m, 4H), 4.91-4.72 (m, 1H), 3.85-3.69 (m, 8H), 2.26-2.15 (m, 1H), 1.82-1.67 (m, 1H), 1.50 (brs, 5H), 1.51-1.23 (m, 9H), 0.68-0.59 (m, 9H), -0.08 (s, 3H), -0.23 to -0.38 (m, 2H) ppm; ${}^{13}C{}^{1}H$ NMR (100 MHz, CDCl₃, rotamers) δ 154.3, 138.9 (d, J = 7.6 Hz), 138.0 (d, J = 6.4 Hz), 133.3 (133.1), 128.4 (d, J = 6.9 Hz) (128.1), 127.0 (126.8), 125.6, 125.8 (125.7), 80.4 (80.8), 77.8 (d, J = 5.4 Hz) (79.3), 74.3 (d, J = 151.9 Hz) (74.8), 54.4 (d, J = 7.2 Hz) (54.5), 52.6, 52.7 (52.4), 46.6 (46.3), 32.6 (32.2), 28.6 (28.1), 25.5 (d, J = 4.5 Hz), 17.8 (17.7), -4.8 (-4.9), -5.4 (-5.7) ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 28.7 (26.6) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₂₃H₃₉ClNO₆PSiNa⁺ 542.1865, found 542.1871.

(25,35)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-2-(4-chlorophenyl)-2-(dimethoxyphosphoryl)pyrrolidine-1-carboxylate (**9n**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, $R_f = 0.3$). White solid (187 mg, 72%). [α]_D²⁵ +6.8 (*c* 1.00, CHCl₃); mp 132–133 °C; IR (film) ν_{max} 2916, 2850, 1711, 1384, 1249, 1054, 833, 771 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 7.48–7.27 (m, 4H), 4.55–4.47 (m, 1H), 3.90–3.61 (m, 5H), 3.60–3.40 (m, 3H), 1.85–1.76 (m, 0.36H), 1.73–1.67 (m, 0.64H), 1.66–1.56 (m, 1H), 1.55–1.26 (m, 9H), 0.97–0.86 (m, 9H), 0.19–0.10 (m, 3H), 0.09–0.01 (m, 3H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃, rotamers) δ 154.7 (154.2), 137.6 (137.1), 133.3, 128.6 (128.3), 127.9 (128.1), 82.9 (85.1), 80.1 (80.8), 74.9 (d, *J* = 163.4 Hz) (79.5), 53.3 (d, *J* = 6.9 Hz) (53.6, 53.9), 52.1 (d, *J* = 5.8 Hz), 46.9 (47.3), 30.7 (d, *J* = 5.9 Hz) (29.8), 28.6 (28.4), 25.9, 18.2, -4.5 (-4.6), -4.9 ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 23.0 (22.6) ppm; HRMS (ESI-Orbitrap) *m*/*z* [M + Na]⁺ calcd for C₂₃H₃₉ClNO₆PSiNa⁺ 542.1865, found 542.1868.

(2R,3S)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-2-(4-chlorophenyl)-2-(dimethoxyphosphoryl)pyrrolidine-1-carboxylate (9n-2). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, $R_f = 0.3$). Colorless oil (39 mg, 15%). $[\alpha]_{D}^{24}$ +20.3 (c 2.00, CHCl₃); IR (film) ν_{max} 2953, 2854, 1693, 1388, 1249, 1054, 1021, 833, 778 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 7.30-7.20 (m, 4H), 4.90-4.76 (m, 1H), 3.86-3.69 (m, 8H), 2.28-2.13 (m, 1H), 1.79-1.65 (m, 1H), 1.50-1.22 (m, 9H), 0.67-0.60 (m, 9H), -0.26 to -0.36 (m, 3H) ppm; ${}^{13}C{}^{1}H$ NMR (100 MHz, CDCl₃, rotamers) δ 154.5, 134.4 (d, J = 6.9 Hz) (135.4), 132.6 (132.4), 129.1 (d, J = 5.0 Hz) (129.2), 127.3 (127.0), 80.3 (80.8), 77.7 (d, I = 5.3 Hz) (79.1), 74.2 (d, I = 5.4 Hz) (74.6), 54.4, 54.3 (54.7), 52.5 (d, I = 8.0 Hz), 46.3 (46.51), 32.5 (32.1), 28.6 (28.1), 25.5 (d, J = 5.0 Hz), 17.8 (17.7), -4.8 (-4.9), -5.3 (-5.4)ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 29.0 (26.9, 25.1) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₂₃H₃₉ClNO₆PSiNa⁺ 542.1865, found 542.1868.

(2S,3S)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-2-(dimethoxyphosphoryl)-2-(4-methoxyphenyl)pyrrolidine-1-carboxylate (90). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, $R_f = 0.3$). Colorless oil (139 mg, 54%). $[\alpha]_D^{23}$ +4.6 (c 3.00, CHCl₃); IR (film) ν_{max} 2953, 1711, 1506, 1396, 1249, 1054, 833, 551 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 7.46-7.29 (m, 2H), 6.94-6.80 (m, 2H), 4.61-4.50 (m, 1H), 3.95-3.82 (m, 1H), 3.80 (s, 3H), 3.75-3.69 (m, 3H), 3.69-3.56 (m, 1H), 3.56-3.33 (m, 3H), 1.75-1.59 (m, 2H), 1.55-1.35 (m, 9H), 0.98-0.89 (m, 9H), 0.21-0.13 (m, 3H), 0.12-0.06 (m, 3H) ppm; ${}^{13}C{}^{1}H$ NMR (100 MHz, CDCl₃, rotamers) δ 158.8, 154.2 (154.9), 131.1 (130.2), 127.5 (127.7), 126.1, 113.8, 113.4 (114.2), 82.6 (84.7), 79.7 (80.5), 74.9 (d, J = 163.6 Hz) (74.6), 55.3 (55.7), 53.3 (53.8), 51.8, 46.9 (47.4), 30.6 (d, J = 6.4 Hz) (29.7), 28.6, 28.5 (28.4), 25.9, 18.2, -4.6, -4.9 ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 23.5 (22.8) ppm; HRMS (ESI-Orbitrap) m/z [M + H]⁺ calcd for $C_{24}H_{43}NO_7PSi^+$ 516.2541, found 516.2549.

(2R,3S)-tert-Butyl 3-(tert-butyldimethylsilyloxy)-2-(dimethoxyphosphoryl)-2-(4-methoxyphenyl)pyrrolidine-1-carboxylate (90-2). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, $R_f = 0.3$). Colorless oil (70 mg, 27%). $[\alpha]_D^{24}$ +14.6 (c 2.00, CHCl₃); IR (film) ν_{max} 2953, 1697, 1506, 1381, 1256, 1058, 834, 558 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) & 7.27-7.16 (m, 2H), 6.84-6.74 (m, 2H), 4.87-4.73 (m, 1H), 3.81-3.74 (m, 7H), 3.74-368 (m, 4H), 2.24-2.12 (m, 1H), 1.89-1.59 (m, 2H), 1.51-1.48 (m, 5H), 1.26-1.21 (m, 4H), 0.68-0.60 (m, 9H), -0.09 (m, 3H), -0.25 to -0.38 (m, 3H) ppm; $^{13}C{^{1}H}$ NMR (100 MHz, CDCl₃, rotamers) δ 158.4, 154.4 (154.7), 128.7 (d, I = 5.3 Hz) (128.9), 127.6 (d, I = 6.0 Hz), 112.8 (112.4), 80.0 (80.4), 79.0 (d, J = 7.3 Hz), 74.0 (d, J = 151.6 Hz) (74.5), 55.4 (55.5), 54.3, 54.2 (54.4), 52.4 (d, *J* = 7.9 Hz), 46.2 (46.5), 32.4 (d, *J* = 3.6 Hz) (32.0), 28.6 (28.1), 25.6 (d, I = 5.0 Hz) (26.0), 17.8 (d, I =6.5 Hz), -4.8 (-4.9), -5.3 (-5.4) ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 29.8 (27.5) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for $C_{24}H_{42}NO_7PSiNa^+$ 538.2360, found 538.2364.

 $(2\bar{s},3\bar{s})$ -tert-Butyl 2-benzyl-3-(tert-butyldimethylsilyloxy)-2-(dimethoxyphosphoryl)pyrrolidine-1-carboxylate (**9p**). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, R_f = 0.3). Colorless oil (180 mg, 72%). $[\alpha]_D^{24}$ -26.4 (*c* 2.00, CHCl₃); IR (film) ν_{max} 2949, 1704, 1373, 1252, 1124, 1032, 833, 771 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 7.33–7.17 (m, 5H), 4.27–4.00 (m, 2H), 3.85–3.73 (m, 6H), 3.66– 3.48 (m, 1H), 3.32–2.99 (m, 2H), 2.29–2.04 (m, 1H), 1.53 (s, 9H), 1.49–1.44 (m, 1H), 1.01–0.91 (m, 9H), 0.13–0.00 (m, 6H) ppm; ¹³C{¹H} NMR (100 MHz, CDCl₃, rotamers) δ 153.6 (154.6), 136.3 (136.2), 131.1, 130.0 (128.5), 128.2, 126.7 (126.8), 79.6 (81.0), 75.9 (d, *J* = 108.7 Hz) (74.9), 70.3 (d, *J* = 8.7 Hz) (68.7), 53.3 (d, *J* = 7.7 Hz) (52.8), 52.3 (d, *J* = 8.3 Hz) (52.7), 45.9, 34.4 (d, *J* = 7.8 Hz) (35.3), 29.5 (29.2), 28.6 (28.5), 25.8, 18.1, –3.8 (–4.2), –4.6 ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 26.3 (25.5) ppm; HRMS (ESI-Orbitrap) *m*/*z* [M + Na]⁺ calcd for C₂₄H₄₂NO₆PSiNa⁺ 522.2411, found 522.2415.

(2S,3S)-tert-Butyl 2-(p-methylbenzene)-3-(tert-butyldimethylsilyloxy)-2-(dimethoxyphosphoryl)pyrrolidine-1-carboxylate (9q). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, $R_f = 0.3$). White semisolid (149 mg, 58%). $[\alpha]_{\rm D}^{25}$ –33.2 (c 1.00, CHCl₃); IR (film) $\nu_{\rm max}$ 2927, 1708, 1377, 1252, 1127, 1036, 775 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 7.19-7.02 (m, 4H), 4.26-4.05 (m, 2H), 3.88-3.74 (m, 6H), 3.63-3.49 (m, 1H), 3.25-2.99 (m, 2H), 2.34-2.30 (m, 3H), 1.77 (brs, 1H), 1.57–1.53 (m, 9H), 1.47–1.45 (m, 1H), 1.02–0.90 (m, 9H), 0.13–0.00 (m, 6H) ppm; ${}^{13}C{}^{1}H{}$ NMR (100 MHz, CDCl₃, rotamers) δ 153.6 (154.7), 137.6, 136.1 (136.4), 132.0 (131.2), 128.2 (128.0), 127.4 (127.6), 79.6 (81.0), 75.8 (d, J = 105.7 Hz) (74.8), 70.3 (d, J = 14.1 Hz) (68.7), 53.4 (d, J = 7.2 Hz) (52.8), 52.3 (d, J = 7.7 Hz) (52.8), 46.0 (44.9), 34.2 (d, J = 7.8 Hz) (35.2), 29.4 (29.2), 28.6 (d, J = 8.0 Hz), 25.9, 21.4, 18.1, -3.7 (-4.1), -4.6 ppm; 31 P NMR (162 MHz, CDCl₃, rotamers) δ 26.4 (25.6) ppm; HRMS (ESI-Orbitrap) m/z [M + Na]⁺ calcd for C₂₅H₄₄NO₆PSiNa⁺ 536.25677, found 536.2570.

(25,35)-tert-Butyl 2-allyl-3-(tert-butyldimethylsilyloxy)-2-(dimethoxyphosphoryl)pyrrolidine-1-carboxylate (9r). The title compound was purified by column chromatography (petroleum ether/ethyl acetate = 2:1, R_f = 0.3). Yellow oil (142 mg, 63%). $[\alpha]_D^{25}$ -17.5 (c 1.00, CHCl₃); IR (film) ν_{max} 2953, 1704, 1377, 1249, 1149, 1036, 837, 767 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, rotamers) δ 5.63-5.52 (m, 1H), 5.23-5.14 (m, 2H), 4.25-4.13 (m, 1H), 3.79-3.71 (m, 6H), 3.62-3.53 (m, 1H), 3.52-3.24 (m, 2H), 2.63-2.52 (m, 1H), 2.45-2.30 (m, 1H), 1.95-1.86 (m, 1H), 1.50-1.44 (m, 9H), 0.93 (s, 9H), 0.10 (s, 3H), 0.08 (s, 3H) ppm; ¹³C{¹H} NMR (100 MHz, DMSO- d_6 , Temp = 75 °C) δ 152.3, 132.4, 118.7, 75.0, 67.5, 66.0, 52.1 (d, *J* = 7.1 Hz), 51.5 (d, *J* = 7.3 Hz), 44.8, 33.7 (d, *J* = 6.7 Hz), 28.2, 27.7, 25.2, 17.2, -4.9, -5.2 ppm; ³¹P NMR (162 MHz, CDCl₃, rotamers) δ 25.9 (25.0) ppm; HRMS (ESI-Orbitrap) *m*/*z* [M + Na]⁺ calcd for C₂₀H₄₀NO₆PSiNa⁺ 472.2255, found 472.2257.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.joc.1c00935.

Copies of ¹H, ¹³C{¹H}, ³¹P NMR spectra, HPLC data, and X-ray structural data (PDF)

Accession Codes

CCDC 2071721–2071723 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

AUTHOR INFORMATION

Corresponding Authors

Bang-Guo Wei – Department of Natural Medicine, School of Pharmacy, Fudan University, Shanghai 201203, China;
orcid.org/0000-0003-3470-6741; Email: bgwei1974@ fudan.edu.cn

Chang-Mei Si – Department of Natural Medicine, School of Pharmacy, Fudan University, Shanghai 201203, China; Email: sicm@fudan.edu.cn

Authors

- **Zhao-Dan Chen** Department of Natural Medicine, School of Pharmacy, Fudan University, Shanghai 201203, China **Wen-Ke Xu** – Department of Natural Medicine, School of
- Pharmacy, Fudan University, Shanghai 201203, China Jia-Ming Guo – Department of Natural Medicine, School of Pharmacy, Fudan University, Shanghai 201203, China
- Ling Chen Department of Natural Medicine, School of Pharmacy, Fudan University, Shanghai 201203, China
- **Guo-Qiang Lin** Department of Natural Medicine, School of Pharmacy, Fudan University, Shanghai 201203, China; Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.joc.1c00935

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank the National Natural Science Foundation of China (21772027 to B.-G. Wei and 21702032 to C.-M. Si) for financial support. The authors also thank Dr. Han-Qing Dong (Arvinas, Inc.) for helpful suggestions.

REFERENCES

(1) Selected publications: (a) Aminophosphonic and Aminophosphinic Acids: Chemistry and Biological Activity, 5th ed.; Kuhkhar, V. P., Hudson, H. R., Eds.; Wiley: Chichester, 2000. (b) Kalla, R. M. N.; Bae, J.; Kim, I. Catalyst-free ultrasonic-promoted multicomponent synthesis of tertiary α -amino phosphonates. New J. Chem. 2017, 41, 6653-6660. (c) Lin, B.; Shi, S.; Lin, R.; Cui, Y.; Fang, M.; Tang, G.; Zhao, Y. Cobalt-Catalyzed Oxidative C(sp3)-H Phosphonylation for α -Aminophosphonates via C(sp3)-H/P(O)-H Coupling. J. Org. Chem. 2018, 83, 6754-6761. (d) Chen, T.-T.; Wang, A.-E.; Huang, P.-Q. Chemoselective Synthesis of α -Amino- α -cyanophosphonates by Reductive Gem-Cyanation-Phosphonylation of Secondary Amides. Org. Lett. 2019, 21, 3808-3812. (e) Huang, Q.; Zhu, L.; Yi, D.; Zhao, X.; Wei, W. Silver-mediated aminophosphinoylation of propargyl alcohols with aromatic amines and H-phosphine oxides leading to α aminophosphine oxides. Chin. Chem. Lett. 2020, 31, 373-376. (f) Chen, D.-H.; Sun, W.-T.; Zhu, C.-J.; Lu, G.-S.; Wu, D.-P.; Wang, A.-E.; Huang, P.-Q. Enantioselective Reductive Cyanation and Phosphonylation of Secondary Amides by Iridium and Chiral Thiourea Sequential Catalysis. Angew. Chem., Int. Ed. 2021, 60, 8827-8831. (g) Cao, H.-Q.; Li, J.-K.; Zhang, F.-G.; Cahard, D.; Ma, J.-A. Asymmetric Synthesis of Chiral Amino Carboxylic-Phosphonic Acid Derivatives. Adv. Synth. Catal. 2021, 363, 688-729.

(2) Selected publications: (a) Chen, M.-H.; Chen, Z.; Song, B.-A.; Bhadury, P. S.; Yang, S.; Cai, X.-J.; Hu, D.-Y.; Xue, W.; Zeng, S. Synthesis and Antiviral Activities of Chiral Thiourea Derivatives Containing an α -Aminophosphonate Moiety. J. Agric. Food Chem. **2009**, 57, 1383–1388. (b) Occhipinti, A.; Berlicki, L.; Giberti, S.; Dziedziola, G.; Kafarski, P.; Forlani, G. Effectiveness and mode of action of phosphonate inhibitors of plant glutamine synthetase. Pest Manage. Sci. **2010**, 66, 51–58. (c) Forlani, G.; Berlicki, L.; Duo, M.; Dziedziola, G.; Giberti, S.; Bertazzini, M.; Kafarski, P. Synthesis and Evaluation of Effective Inhibitors of Plant δ 1-Pyrroline-5-carboxylate Reductase. J. Agric. Food Chem. **2013**, 61, 6792–6798.

(3) (a) Moonen, K.; Laureyn, I.; Stevens, C. V. Synthetic Methods for Azaheterocyclic Phosphonates and Their Biological Activity. *Chem. Rev.* 2004, 104, 6177–6215. (b) Orsini, F.; Sello, G.; Sisti, M. Aminophosphonic acids and derivatives. Synthesis and biological applications. *Curr. Med. Chem.* **2010**, *17*, 264–289. (c) Mucha, A.; Kafarski, P.; Berlicki, L. Remarkable Potential of the α -Aminophosphonate/Phosphinate Structural Motif in Medicinal Chemistry. *J. Med. Chem.* **2011**, *54*, 5955–5980.

(4) For representative publications, see: (a) Pratt, R. F. Inhibition of a class C β -lactamase by a specific phosphonate monoester. *Science* **1989**, 246, 917–919. (b) Ali, N. a. S.; Zakir, S.; Patel, M.; Farooqui, M. Synthesis of new α -aminophosphonate system bearing Indazole moiety and their biological activity. *Eur. J. Med. Chem.* **2012**, 50, 39–43.

(5) Kafarski, P.; Lejczak, B. Biological activity of aminophosphonic acids. *Phosphorus, Sulfur Silicon Relat. Elem.* **1991**, 63, 193–215.

(6) Huang, J.; Chen, R. An overview of recent advances on the synthesis and biological activity of α -aminophosphonic acid derivatives. *Heteroat. Chem.* **2000**, *11*, 480–492.

(7) Poola, S.; Nagaripati, S.; Tellamekala, S.; Chintha, V.; Kotha, P.; Yagani, J. R.; Golla, N.; Cirandur, S. R. Green synthesis, antibacterial, antiviral and molecular docking studies of α -aminophosphonates. *Synth. Commun.* **2020**, *50*, 2655–2672.

(8) Vassiliou, S.; Weglarz-Tomczak, E.; Berlicki, L.; Pawelczak, M.; Nocek, B.; Mulligan, R.; Joachimiak, A.; Mucha, A. Structure-Guided, Single-Point Modifications in the Phosphinic Dipeptide Structure Yield Highly Potent and Selective Inhibitors of Neutral Aminopeptidases. J. Med. Chem. 2014, 57, 8140–8151.

(9) (a) Chukka, G.; Muppuru, K. M.; Banothu, V.; Battu, R. S.; Addepally, U.; Gandavaram, S. P.; Chamarthi, N. R.; Mandava, R. V. B. Microwave-Assisted One-Pot Synthesis of New α -Aminophosphonates Using ZnBr₂-SiO₂ as a Catalyst under Solvent-Free Conditions and Their Anticancer Activity. *ChemistrySelect* **2018**, *3*, 9778–9784. (b) Aita, S.; Badavath, V. N.; Gundluru, M.; Sudileti, M.; Nemallapudi, B. R.; Gundala, S.; Zyryanov, G. V.; Chamarti, N. R.; Cirandur, S. R. Novel α -Aminophosphonates of imatinib Intermediate: Synthesis, anticancer Activity, human Abl tyrosine kinase Inhibition, ADME and toxicity prediction. *Bioorg. Chem.* **2021**, *109*, 104718.

(10) (a) Van Speybroeck, V.; Moonen, K.; Hemelsoet, K.; Stevens, C. V.; Waroquier, M. Unexpected Four-Membered over Six-Membered Ring Formation during the Synthesis of Azaheterocyclic Phosphonates: Experimental and Theoretical Evaluation. *J. Am. Chem. Soc.* **2006**, *128*, 8468–8478. (b) Moonen, K.; Dieltiens, N.; Stevens, C. V. Synthesis of 2-Phosphonopyrroles via a One-Pot RCM/ Oxidation Sequence. *J. Org. Chem.* **2006**, *71*, 4006–4009.

(11) Harakeh, S.; Khan, I.; Almasaudi, S. B.; Azhar, E. I.; Al-Jaouni, S.; Niedzweicki, A. Role of Nutrients and Phyto-compounds in the Modulation of Antimicrobial Resistance. *Curr. Drug Metab.* **2017**, *18*, 858–867.

(12) (a) Newman, D. J.; Cragg, G. M. Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010. *J. Nat. Prod.* **2012**, 75, 311–335. (b) Kramer, G. J.; Mohd, A.; Schwager, S. L. U.; Masuyer, G.; Acharya, K. R.; Sturrock, E. D.; Bachmann, B. O. Interkingdom pharmacology of angiotensin-1 converting enzyme inhibitor phosphonates produced by Actinomycetes. *ACS Med. Chem. Lett.* **2014**, *5*, 346–351.

(13) Abas, S.; Erdozain, A. M.; Keller, B.; Rodriguez-Arevalo, S.; Callado, L. F.; Garcia-Sevilla, J. A.; Escolano, C. Neuroprotective Effects of a Structurally New Family of High Affinity Imidazoline I2 Receptor Ligands. *ACS Chem. Neurosci.* **201**7, *8*, 737–742.

(14) (a) Audran, G.; Bosco, L.; Bremond, P.; Franconi, J.-M.; Koonjoo, N.; Marque, S. R. A.; Massot, P.; Mellet, P.; Parzy, E.; Thiaudiere, E. Enzymatically shifting nitroxides for EPR spectroscopy and Overhauser-enhanced magnetic resonance imaging. *Angew. Chem., Int. Ed.* **2015**, *54*, 13379–13384. (b) Duttagupta, I.; Jugniot, N.; Audran, G.; Franconi, J.-M.; Marque, S. R. A.; Massot, P.; Mellet, P.; Parzy, E.; Thiaudiere, E.; Vanthuyne, N. Selective On/Off-Nitroxides as Radical Probes to Investigate Non-radical Enzymatic Activity by Electron Paramagnetic Resonance. *Chem. - Eur. J.* **2018**, *24*, 7615–7619. (15) Zecchini, G. P.; Paradisi, M. P.; Torrini, I.; Lucente, G. A convenient route to pyrrolidine-2-phosphonic acid dipeptides. *Int. J. Pept. Protein Res.* **1989**, *34*, 33–36.

(16) Qian, R.-Z.; Kalina, T.; Horak, J.; Giberti, S.; Forlani, G.; Hammerschmidt, F. Preparation of Phosphonic Acid Analogues of Proline and Proline Analogues and Their Biological Evaluation as δ^1 -Pyrroline-5-carboxylate Reductase Inhibitors. *ACS Omega.* **2018**, *3*, 4441–4452.

(17) Rao, H.-H; Jin, Y.; Fu, H.; Jiang, Y.-Y.; Zhao, Y.-F. A Versatile and Efficient Ligand for Copper-Catalyzed Formation of C-N, C-O, and P-C Bonds: Pyrrolidine-2-Phosphonic Acid Phenyl Monoester. *Chem. - Eur. J.* **2006**, *12*, 3636–3646.

(18) Haji, M. Multicomponent reactions: A simple and efficient route to heterocyclic phosphonates. *Beilstein J. Org. Chem.* **2016**, *12*, 1269–1301.

(19) Selected publications: (a) Yadav, J. S.; Reddy, B. V. S.; Madan, C. Montmorillonite clay-catalyzed one-pot synthesis of α -amino phosphonates. Synlett 2001, 2001, 1131-1133. (b) Davis, F. A.; Wu, Y.; Xu, H.; Zhang, J. Asymmetric Synthesis of Cis-5-Substituted Pyrrolidine 2-Phosphonates Using Metal Carbenoid NH Insertion and δ -Amino β -Ketophosphonates. Org. Lett. 2004, 6, 4523-4525. (c) Crich, D.; Ranganathan, K. Stereochemical Memory Effects in Alkene Radical Cation/Anion Contact Ion Pairs: Effect of Substituents, and Models for Diastereoselectivity. J. Am. Chem. Soc. 2005, 127, 9924-9929. (d) Davis, F. A.; Xu, H.; Wu, Y.; Zhang, J. Asymmetric Synthesis of Polyfunctionalized Pyrrolidines from Sulfinimine-Derived Pyrrolidine 2-Phosphonates. Synthesis of Pyrrolidine 225C. Org. Lett. 2006, 8, 2273-2276. (e) Matveeva, E. D.; Podrugina, T. A.; Prisyazhnoi, M. V.; Rusetskaya, I. N.; Zefirov, N. S. Three-component catalytic method for synthesis of α -amino phosphonates with the use of α -amino acids as amine component. Russ. Chem. Bull. 2007, 56, 798-805. (f) Bhagat, S.; Chakraborti, A. K. Zirconium(IV) Compounds As Efficient Catalysts for Synthesis of α-Aminophosphonates. J. Org. Chem. 2008, 73, 6029-6032. (g) Mumford, P. M.; Tarver, G. J.; Shipman, M. Four-Component Reaction for the Preparation of α -Amino Phosphonates from Methyleneaziridines. J. Org. Chem. 2009, 74, 3573-3575. (h) Tibhe, G. D.; Bedolla-Medrano, M.; Cativiela, C.; Ordonez, M. Phenylboronic acid as efficient and eco-friendly catalyst for the onepot, three-component synthesis of α -aminophosphonates under solvent-free conditions. Synlett 2012, 23, 1931-1936. (i) Hu, G.; Chen, W.; Ma, D.; Zhang, Y.; Xu, P.; Gao, Y.; Zhao, Y. Silver-Catalyzed, Aldehyde-Induced α -C-H Functionalization of Tetrahydroisoquinolines with Concurrent C-P Bond Formation/N-Alkylation. J. Org. Chem. 2016, 81, 1704-1711.

(20) Gao, Y.; Huang, Z.; Zhuang, R.; Xu, J.; Zhang, P.; Tang, G.; Zhao, Y. Direct Transformation of Amides into α -Amino Phosphonates via a Reductive Phosphination Process. *Org. Lett.* **2013**, *15*, 4214–4217.

(21) Selected publications: (a) Odinets, I. L.; Artyushin, O. I.; Lyssenko, K. A.; Shevchenko, N. E.; Nenajdenko, V. G.; Roeschenthaler, G.-V. Facile synthesis of cyclic α -perfluoroalkyl- α aminophosphonates. J. Fluorine Chem. **2009**, 130, 662–666. (b) Odinets, I. L.; Artyushin, O. I.; Shevchenko, N.; Petrovskii, P. V.; Nenajdenko, V. G.; Roschenthaler, G.-V. Efficient synthesis of substituted cyclic α -aminophosphonates. Synthesis **2009**, 2009, 577– 582. (c) Arizpe, A.; Sayago, F. J.; Jimenez, A. I.; Ordonez, M.; Cativiela, C. Stereodivergent Synthesis of Two Novel α -Aminophosphonic Acids Characterised by a cis-Fused Octahydroindole System. *Eur. J. Org. Chem.* **2011**, 16, 3074–3081. (d) Argueello-Velasco, R. O.; Sanchez-Munoz, G. K.; Viveros-Ceballos, J. L.; Ordonez, M.; Kafarski, P. A Straightforward Synthesis of Six-Membered-Ring Heterocyclic α -Aminophosphonic Acids from N-Acyliminium Ions. J. Heterocycl. Chem. **2019**, 56, 2068–2073.

(22) Selected publications: (a) Han, W.; Ofial, A. R. Iron-catalyzed dehydrogenative phosphonation of N,N-dimethylanilines. *Chem. Commun.* **2009**, 6023–6025. (b) Yang, D.; Zhao, D.; Mao, L.; Wang, L.; Wang, R. Copper/DIPEA-Catalyzed, Aldehyde-Induced Tandem Decarboxylation-Coupling of Natural α -Amino Acids and

Phosphites or Secondary Phosphine Oxides. J. Org. Chem. 2011, 76, 6426–6431. (c) Rashid, Z.; Naeimi, H.; Ghahremanzadeh, R. Highly efficient one-pot four-component Kabachnik-Fields synthesis of novel α -amino phosphonates under solvent-free and catalyst-free conditions. RSC Adv. 2015, 5, 99148–99152. (d) Robertson, G. P.; Farley, A. J. M.; Dixon, D. J. Bifunctional iminophosphorane catalyzed enantio-selective ketimine phospha-Mannich reaction. Synlett 2015, 27, 21–24. (e) Cai, J.; Liu, Y.; Jiang, Y.; Yang, Y. Iron-catalyzed aerobic oxidative phosphonation of N-aryl tetrahydroisoquinolines. Phosphorus, Sulfur Silicon Relat. Elem. 2017, 192, 1068–1073.

(23) Selected publications: (a) Chen, Q.; Yuan, C. A new and convenient asymmetric synthesis of α -amino- and α -alkyl- α -aminophosphonic acids using N-tert-butylsulfinyl imines as chiral auxiliaries. Synthesis 2007, 2007, 3779-3786. (b) Gazizov, M. B.; Khairullin, R. A.; Alekhina, A. I.; Litvinov, I. A.; Krivolapov, D. B.; Latypov, S. K.; Balandina, A. A.; Musin, R. Z.; Sinyashin, O. G. New products of the reaction of aldimines with dialkyl phosphites. Mendeleev Commun. 2008, 18, 262-264. (c) Lewkowski, J.; Tokarz, P.; Lis, T.; Slepokura, K. Stereoselective addition of dialkyl phosphites to di-salicylaldimines bearing the (R,R)-1,2-diaminocyclohexane moiety. Tetrahedron 2014, 70, 810-816. (d) Balint, E.; Tajti, A.; adam, A.; Csontos, I.; Karaghiosoff, K.; Czugler, M.; abranyi-Balogh, P.; Keglevich, G. The synthesis of α -aryl- α -aminophosphonates and α -aryl- α -aminophosphine oxides by the microwave-assisted Pudovik reaction. Beilstein J. Org. Chem. 2017, 13, 76-86. (e) Nakamura, S.; Hayama, D. Enantioselective Reaction of 2H-Azirines with Phosphite Using Chiral Bis(imidazoline)/Zinc(II) Catalysts. Angew. Chem., Int. Ed. 2017, 56, 8785-8789.

(24) Le Moigne, F.; Mercier, A.; Tordo, P. β -Phosphorylated cyclic nitroxides. 2. Synthesis of pyrrolidin- and piperidin-2-ylphosphonates and the corresponding stable nitroxides. *Tetrahedron Lett.* **1991**, *32*, 3841–3844.

(25) Haak, E.; Bytschkov, I.; Doye, S. A one-pot procedure for the synthesis of α -amino phosphonates from alkynes. *Eur. J. Org. Chem.* **2002**, 3, 457–463.

(26) Han, J.; Paton, R.; Xu, B.; Hammond, G. Synthesis of Cyclic α -Aminophosphonates through Copper-Catalyzed Enamine Activation. *Synthesis* **2013**, *45*, 463–470.

(27) (a) Davis, F.-A.; Xu, H.; Wu, Y.; Zhang, J. Asymmetric Synthesis of Polyfunctionalized Pyrrolidines from Sulfinimine-Derived Pyrrolidine 2-Phosphonates. Synthesis of Pyrrolidine 225C. Org. Lett. 2006, 8, 2273–2276. (b) Davis, F.-A.; Zhang, J.-Y.; Qiu, H.; Wu, Y.-Z. Asymmetric Synthesis of cis- and trans-2,5-Disubstituted Pyrrolidines from 3-Oxo Pyrrolidine 2-Phosphonates: Synthesis of (+)-Preussin and Analogs. Org. Lett. 2008, 10, 1433–1436.

(28) (a) Si, C.-M.; Huang, W.; Du, Z.-T.; Wei, B.-G.; Lin, G.-Q. Diastereoconvergent Synthesis of trans-5-Hydroxy-6-Substituted-2-Piperidinones by Addition-Cyclization-Deprotection Process. Org. Lett. 2014, 16, 4328-4331. (b) Mao, Z.-Y.; Liu, Y.-W.; Han, P.; Dong, H.-Q.; Si, C.-M.; Wei, B.-G.; Lin, G.-Q. Regio- and Stereoselective Cascades via Aldol Condensation and 1,3-Dipolar Cycloaddition for Construction of Functional Pyrrolizidine Derivatives. Org. Lett. 2018, 20, 1090-1093. (c) Han, P.; Mao, Z.-Y.; Si, C.-M.; Zhou, Z.; Wei, B.-G.; Lin, G.-Q. Stereoselective Synthesis of Pyrido- and Pyrrolo[1,2-c][1,3]oxazin-1-ones via a Nucleophilic Addition-Cyclization Process of N,O-Acetal with Ynamides. J. Org. Chem. 2019, 84, 914-923. (d) Mao, Z.-Y.; Liu, Y.-W.; Ma, R.-J.; Ye, J.-L.; Si, C.-M.; Wei, B.-G.; Lin, G.-Q. Divergent synthesis of Nheterocyclic 1,6-enynes through a zinc-catalyzed decarboxylative A3 reaction. Chem. Commun. 2019, 55, 14170-14173. (f) Wang, C.; Mao, Z.-Y.; Liu, Y.-W.; Wang, Q.-E.; Si, C.-M.; Wei, B.-G.; Lin, G.-Q. Stereoselective Intermolecular [4 + 2] Process of N,O-acetals with Terminal Alkynes for Construction of Functional cis-Pyrido and Pyrrolo[1,2-c][1,3]oxazin-1-ones. Adv. Synth. Catal. 2020, 362, 822-831.

(29) Padwa, A.; Rashatasakhon, P.; Rose, M. Triflic anhydride mediated cyclization of 5-hydroxy-substituted pyrrolidinones for the preparation of α -trifluoromethylsulfonamido furans. *J. Org. Chem.* **2003**, *68*, 5139–5146.

The Journal of Organic Chemistry

(30) Dmitriev, M. E.; Golovash, S. R.; Borodachev, A. V.; Ragulin, V. V. Mechanism of Phosphorus-Carbon Bond Formation in the Amidoalkylation of Phosphonous Carboxylic Acids. *J. Org. Chem.* **2021**, *86*, 593–600.

(31) Larsen, C. H.; Ridgway, B. H.; Shaw, J. T.; Smith, D. M.; Woerpel, K. A. Stereoselective C-Glycosylation Reactions of Ribose Derivatives: Electronic Effects of Five-Membered Ring Oxocarbenium Ions. J. Am. Chem. Soc. **2005**, 127, 10879–10884.

(32) Abdul-Rashed, S.; Alachouzos, G.; Brennessel, W.-W.; Frontier, A.-J. One-Pot Double-Annulation Strategy for the Synthesis of Unusual Fused Bis-Heterocycles. *Org. Lett.* **2020**, *22*, 4350–4354.

(33) Zheng, X.; Feng, C.-G.; Ye, J.-L.; Huang, P.-Q. Samarium Diiodide Promoted Generation and Asymmetric Hydroxyalkylation of *N*,*O*-Diprotected (3S)-3-Pyrrolidinol 2-Carbanions. *Org. Lett.* **2005**, *7*, 553–556.

(34) Zhang, Y.; Yan, Q.; Zi, G.; Hou, G. Enantioselective Direct Synthesis of Free Cyclic Amines via Intramolecular Reductive Amination. *Org. Lett.* **2017**, *19*, 4215–4218.

(35) Lima, F.; Sharma, U. K.; Grunenberg, L.; Saha, D.; Johannsen, S.; Sedelmeier, J.; Van der Eycken, E. V.; Ley, S. V. A Lewis Base Catalysis Approach for the Photoredox Activation of Boronic Acids and Esters. *Angew. Chem., Int. Ed.* **2017**, *56*, 15136–15140.

(36) Antonopoulou, G.; Barbayianni, E.; Magrioti, V.; Cotton, N.; Stephens, D.; Constantinou-Kokotou, V.; Dennis, E.-A.; Kokotos, G. Structure–activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A2 enzymes. *Bioorg. Med. Chem.* **2008**, *16*, 10257–10269.

(37) Vu, H.-D.; Renault, J.; Roisnel, T.; Gouault, N.; Uriac, P. Methanesulfonic Acid Mediated Cyclization and Meyer–Schuster Rearrangement of γ -Amino-ynones: Access to Enantiopure Pyrrolidine Exocyclic Vinylogous Amides. *Eur. J. Org. Chem.* **2014**, 2014, 4506–4514.

(38) Ruchirawat, S.; Disadee, W. A one-pot, metal-free approach to bicyclic 2-pyridones. *Org. Chem. Front.* **2017**, *4*, 2026–2030.